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ABSTRACT
UNIVERSAL SWINE INFLUENZA ANTIGEN AND VACCINE
ZHAO WANG
2018
Swine influenza A viruses pose a serious concern for global health and
worldwide swine industry considering their evasion from vaccine-induced
immune responses. Formulation of effective influenza vaccines can be
complicated by both antigenic shift to a different subtype of hemagglutinin (HAs)
and antigenic drift within a particular HA subtype. To address these concerns, we
employed a systematic approach to determine the antigenic determinants of
swine influenza A viruses by focusing on H1 and H3 subtypes. In parallel, we
used a cross-disciplinary approach including structural biology and modeling,
virology, and immunology to identify swine influenza A virus-derived HA fusion
intermediates broadly reactive to antibodies elicited from various strains or
subtypes of swine influenza A viruses. Finally, we conducted a swine influenza
vaccine study to evaluate the protective efficacy of a newly identified HA fusion
intermediate. The vaccine candidate, when administered into pigs, protected
swine against infections by swine influenza H1N1 and H3N2 viruses.
For the antigenicity study, we performed a detailed analysis of the
antigenic determinants of the Hemagglutinin (HA) protein of pdm09 strain
(subtype H1N1) by the HA peptide array in Enzyme-linked immunosorbent assay

xvii
with immune serum from experimental infected pigs by swine influenza A viruses
(SIVs). The peptide array contains 139 peptides spanning the HA protein of
H1N1pdm09 and peptides are 14- or 15-mers with 11 amino acid overlaps. A
panel of swine antisera against SIV H1 clusters α, β, γ, δ-A, δ-B, H1N1pdm09,
and H3 cluster was used in this study and SIVs used for swine hyperimmune
sera production are representative subtypes and clusters of SIV circulating in
North America. The results of these studies identified three immunodominant
peptides, one located in the HA1 (amino acids 57-71) and two in the HA2 (amino
acids 481-495 and 553-566), reactive to its homologous antisera (H1N1pdm09).
Analysis of peptide reactivity with heterologous serum samples revealed that
antibody responses to two HA2 peptides (amino acids 481-495 and 553-566) are
completely conserved among antisera of all H1 clusters. In addition to
H1N1pdm09, HA1 peptide (amino acids 57-71) was reactive to SIV H1 γ antisera
Interestingly, none of peptides in HA peptide array of H1N1pdm09 were reactive
to SIV H3 antisera, despite that this antisera has a HI antibody titer similar to
those of H1 clusters antisera. Structural modeling localized two conserved
immunedominant

determinants

to

the

membrane

proximal external region (MPER) (amino acids 481-495) and the intracytoplasmic
tail (amino acids 553-566) of the HA molecule.
For the HA fusion intermediate project, through a structure-guided sitespecific mutagenesis targeting HA2 A and CD helical domains, we identified a
mutation, named N439G, that attenuated viral replication but the resultant virus
was still recognized by antiviral antibodies. The attenuation was mediated

xviii
probably through the disruption of triple CD helix formation in the viruses. In light
of the fact that N439G virus is highly attenuated in that it may prolong the
exposure of HA fusion intermediate to host B cells toward antibody production,
we next evaluated its vaccination efficacy in pigs. Significantly, pigs receiving
N439G immunizations were substantially protected from both swine influenza A
H1N1 and H3N2.
In summary, the results of our antigenicity study provide an important
foundation for further analyzing the immune response against these B cell
epitopes residing in the HA protein during natural SIV infection and also provide
potential peptide substrates for diagnostic assays and for vaccine strategies. Our
universal vaccine candidate identified from this work should pave the way for
further studies toward developing a universal swine influenza vaccine and
defining a protective mechanism.

1
CHAPTER 1. INTRODUCTION AND OBJECTIVES

1.1

Introduction
Influenza remains a big threat to global health and livestock industry.

There are four types of influenza viruses identified to date. Among them,
influenza A virus (IAV) is the most "successful" genus due to its ability to
frequently alter its segments, thereby resulting in both antigenic drift and shift.
The derived mutant influenza viruses are new to humans and animals with no
pre-existing immunity, which as a result cause annual influenza epidemics and
occasional influenza pandemics. IAV has numerous subtypes depending on
surface proteins hemagglutinin (H1-H17) and neuraminidase (NA1-NA11). The
diversity among influenza virus subtypes and seasonal strains carrying novel
mutations poses a big challenge to develop effective vaccines that offers a solid
protection against all strains. Although the current multivalent IAV vaccine is
helpful to prevent seasonal outbreaks, there is an urgent call for more effective
vaccine that can provide broad protection against multiple IAV strains. Currently,
human seasonal IAV subtypes consist of H1 and H3 HA subtypes, and the N1
and N2 NA subtypes. In the past, pandemic IAV include the H2 HA. Influenza
viruses with other HA subtypes are occasionally able to infect humans, such as
“bird flu” H5N1 virus, however, such spillover infections are rare and there is no
evidence for sustainable human-to-human transmission.
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Swine influenza A viruses pose a concern for global health and worldwide
swine industry. Recent example of human influenza pandemic caused by the
swine-origin triple reassortmant virus in 2009 has demonstrated the devastating
public health consequence. Swine is commonly infected by IAV, primarily
subtypes H1N1, H1N2, and H3N2 (Brockwell-Staats et al., 2009; Vincent et al.,
2017). H1 subtype of SIV has further evolved into clusters α, β, γ, δ-A, δ-B, δ-C,
δ-D, δ-E, and 2009 pandemic H1N1 virus. H3 subtypes has clusters of I, II, III
and IV (Hause et al., 2012). The serum from SIV infected pig has very variable
neutralization activities to SIV strains of the same HA subtype with different
cluster (Hause et al., 2012). The diversity among influenza virus subtypes and
seasonal strains emerged due to mutations makes it difficult to develop a
universal vaccine that offers protection against all SIV strains. Protection efficacy
of influenza vaccines can be complicated by both antigenic shift to a different
subtype of HA and antigenic drift within a particular HA subtype.
The research conducted in this dissertation had been focused on
identifying critical antigenic determinants of HA proteins of circulating SIV strains
in the North America, and developing universal (broadly-reactive) vaccine against
contemporary SIV strains. Currently, the IAV vaccine development primarily aims
to elicit immune responses towards the globular head domain of the HA to elicit
antibodies that are able to block binding of the virus to membrane receptors on
the host cells. Our hypothesis was that vaccine targeting the highly conserved
region of the SIV HA stem domain could generate immunity against a broad
spectrum of influenza strains. Another hypothesis was that viruses with
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attenuated replication capacity through a slow fusion kinetic may prolong its HA
protein exposed to immune system so broadly active antibodies against the
conserved entry mechanism can be generated, which as a result protect swine
against infections by multiple strains or subtypes.

1.2

Objectives

The first objective of this dissertation was to conduct a detailed mapping of the
linear B cell epitopes of the Hemagglutinin (HA) protein of Influenza H1N1pdm09
virus by using synthetic peptide array approach, while the second objective
involved studies to characterize a role of N-terminal HA stem region of swine
influenza A virus including the helix A, B loop, and CD helix in virus replication in
both cell lines and primary porcine tracheal epithelial cells (PTEpC). The other
component of the second objective was to evaluate protective efficacy of an
attenuated virus with a mutation in the CD helix in pigs.
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CHAPTER 2. LITERATURE REVIEW

2.1

Classification of Influenza viruses
Influenza viruses belong to Orthomyxovirus family of enveloped, negative

sense ssRNA viruses. According to the genetic and biological properties of the
viruses, the ICTV classified the Orthomyxoviridae family into seven genus:
Alphainfluenzavirus,

Betainfluenzavirus,

Gammainfluenzvirus,

Deltainfluenzavirus, Isavirus, Thogotovirus and Quaranjavirus (ICTV, 2018;
Lefkowitz et al., 2018). Influenza viruses types A, B, and C have distinct antigenic
properties residing in two major structural proteins (matrix 1 and nucleocapsid)
(Palese & Shaw, 2007). Recently, a new type of influenza virus with bovines as a
primary reservoir, designated influenza type D, has been described (Hause et al.,
2014; Hause et al., 2013). All the types of influenza virions are enveloped, and
have negative-sensed, single-stranded RNA genomes (Figure 1). Both types A
and B have eight genome segments (Table 1), and both types C and D contain
seven genome segments (Table 2). Each segment encodes at least 1 viral gene.
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Figure 1. Diagrammatic illustration of the influenza A virion
The nucleocapsid core (viral ribonucleoprotein, vRNP) contains the eight-segmented
negative sense RNA genome of the IAV and surrounding viral proteins. These segments
are assumed to link together to form a helix during virus assembles at the cell surface.
Underneath the viral envelope is a layer of M1.

Table 1. Genomes and Proteomes of Influenza A and B Viruses

Segment

Length(nt)

Protein(s) encoded

Gene Function

1

~2.34K

PB2

RNA synthesis

2

~2.34K

PB1

RNA synthesis

6

3

~2.23K

PA

RNA synthesis

4

~2.07K

HA

Sialic acid
fusion

5

~1.57K

NP

RNA encapsidation; replication

6

~1.41K

NA

Receptor destruction

M1

Viral assembly and budding

M2

Ion channel

NS1

Innate immunity antagonism

NS2

Nuclear exportation factor

7

8

binding;

membrane

~1.03K

~0.93K

Note: IAV PB1 segment encodes PB1 and PB1-F2; IBV NA segment encodes NA and NB.

Table 2. Genomes and Proteomes of Influenza C and D Viruses

Segment

Length(nt)

Protein(s) encoded

Gene Function

1

~2.37K

PB2

RNA synthesisa

2

~2.36K

PB1

RNA synthesisa

3

~2.18K

P3

RNA synthesisa

4

~2.07K

HEF

Sialic acid binding; receptor
destruction; membrane fusion

5

~1.81K

NP

RNA encapsidation; replicationa

M1

Viral assemblya

M2

Ion channela

NS1

Innate immunity antagonisma

NS2

Nuclear exportation factora

6

7

~1.18K

~0.93K

7

Note: superscripts "a" indicate the gene functions for IDV are predicted based on the
similarities between the genes of ICV and IDV and therefore are to be further validated by
future structural and biological studies.

IAVs are further classified into many subtypes based on antigenicity of
surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). To date, 18
subtypes of HA (H1-H18) and 11 NA (N1-N11) have been described (Shao et al.,
2017; Tong et al., 2013). Influenza B viruses (IBV) have evolved into two
antigenically

and

genetically

distinct

lineages,

Yamagata

and

Victoria

(Vijaykrishna et al., 2015). Influenza C viruses (ICV) have six antigenic lineages,
namely C/Taylor, C/Mississippi, C/Aichi, C/Yamagata, C/Kanagawa, and C/Sao
Paulo (Matsuzaki et al., 2016). IDV have evolved into two lineages represented
by D/swine/Oklahoma/1334/2011 (D/OK) and D/bovine/Oklahoma/660/2013
(D/660)(Collin et al., 2015).
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2.2

Influenza A Virus Replication

Figure 2. Schematic diagram of the influenza viral life cycle
The life cycle of the influenza virus can be divided into the following steps (i) attachment
(receptor binding); (ii) endosomal internalization of the virus into cell (endocytosis); (iii)
uncoating, cytoplasmic transport and nuclear import of viral ribonucleoproteins (vRNPs);
(iv) transcription and replication of the viral RNAs; (v) nuclear exportation and protein
synthesis; (vi) viral progeny assembly, budding and release from the cell membrane (Wu
et al., 2017).

2.2.1 Early stage: Viral attachment, internalization, fusion and uncoating
The binding of the influenza virus to the cellular receptor on a susceptible
cell is the very beginning of IAV replication cycle. The viral spike formed by HA
proteins of IAV binds to the receptor: sialic acid residues present on cellular
glycoproteins (Lanzrein et al., 1994). The attachment of the virus to the cell
induces endocytosis using the clathrin- and caveolin-dependent mechanisms
(Fontana et al., 2012). Membrane fusion occurs at late endosomes. The low pH
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of late endosome (pH 5-6) triggers HA conformation change, resulting in the
fusion between the viral and endosomal membranes. Endosome provides
protons for IAV M2 ion channel and the acidification of internal virion results in
conformational change in the M1, which then weakens interactions between M1
and the viral ribonucleoproteins (vRNPs). In the late endosome, the pre-acidified
viral core is subsequently exposed to a high concentration of K(+), which then
interrupts the interactions between the vRNPs. Finally, the destabilized viral
cores are delivered to the cytosol, and the released polymerase complex and
RNA genome become competent and infectious (Stauffer et al., 2014).
2.2.2 Middle stage: Transcription and replication of viral genome
IAV utilizes “cap-snatching” mechanism to hijack the host’s transcription
machinery and replicates own viral genome. Specifically, it needs to cleave the
cellular mRNAs’ 10 to 15 nucleotides 3’ to the cap structure. This cellular capped
RNA fragment is bound by PB2 cap-binding domain and the 5’ cap of host mRNA
is then removed by PA and subsequently used by the viral polymerase complex
to prime viral transcription. Addition of the 5’ cap and polyadenylation of the 3’
end of the positive sense RNA yield mature IAV mRNAs. In contrast, exact
replication of the viral RNA genome yields viral complimentary RNA, which is
then used as template to yield vRNAs, which can be packaged into progeny
virus. Segments 1-6 encode one protein each and segments 7 and 8 encode for
two proteins each due to splicing. Bicistronic segment 7 produces mRNAs that
are spliced to produce M1 and M2. Similarly, segment 8 produces mRNAs of

10
NS1 and NS2 (Samji, 2009). The viral ribonucleoprotein complex (vRNP), which
comprises NP homo-oligomer, three polymerase subunit proteins (PB2, PB1, and
PA) and viral RNA (vRNA), are then exported from the nucleus. It is
hypothesized that M1's binding to the vRNPs and NS2 is involved in the process
(Samji, 2009).
2.2.3 Late stage: Assembly and budding
IAV forms viral particles at the host cell plasma membrane after the vRNP
accumulates in the cytosol. Virus particles bud from the apical side of polarized
cells, such as airway epithelial cells (Nayak et al., 2004). Membrane proteins HA,
NA, and M2 are transported to the apical plasma membrane. It has been
reported that the HA, NA and M2 proteins that anchor on the cell membranes are
able to interact with viral proteins present in cytosol, especially M1 and NP, to
recruit M1 and vRNP to the site for assembly (Rossman & Lamb, 2011; Wang et
al., 2010a). It has been shown that the tail of M2 is extremely important in the
formation of viral particles, and both HA and NA are required to deform the cell
membrane and the initiation of the virus budding event (Rossman & Lamb, 2011;
Wang et al., 2010a). M1, and its oligomerization, plays an important role to
interact with HA, NA and M2, meanwhile keeps vRNP at the final step of closing
and budding off of the viral particle. It was reported that M2 is the key player to
alter membrane curvature at the neck of the budding virus, causing membrane
scission and the release of the progeny virion (Rossman & Lamb, 2011). Finally,
NA removes sialic acid residue from glycoproteins and glycolipids. The newly
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made viral particle is then released from the plasma membrane for infection of
new cells.

2.3

Influenza Virus Epidemiology and Evolution

2.3.1 Epidemiology of Influenza Viruses
Both type A and B influenza viruses are able to cause epidemics in
humans. These infections can result in a spectrum of clinical disease in humans,
ranging from mild to severe respiratory illness requiring hospitalization and
medical treatment (Monto, 2008; Paul Glezen et al., 2013). ICV infects humans
and is able to cause mild to severe illness in young children (Matsuzaki et al.,
2006). Pathogenesis of newly emerged IDV in humans is yet to be studied.
IAV is a serious public health concern because it causes severe illness
and death in all ages, especially in high-risk populations. IAV is only influenza
virus that causes worldwide influenza pandemics. The first pandemic of influenza
was traced back to 1918 in Spain. The notorious 1918 Spanish A/H1N1 virus
killed approximately 50 million people. Since then, a few small-scale human
influenza pandemics have occurred, respectively, in 1957 (A/H2N2), 1968
(A/H3N2), 1977 (A/H1N1), and more recently the pandemic A/H1N1 “swine flu” in
2009 (Belser & Tumpey, 2018). Worldwide, seasonal influenza epidemics result
in millions cases of severe illness and about 290,000 to 650,000 respiratory
deaths yearly (WHO, 2018). The primary reservoir of influenza A viruses (IAV) is
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migratory waterfowl. However IAV have rapidly adapted to infect and transmit
between a variety of avian and mammalian species. IAV also has a high level of
diversity in terms of genetic differences. In contrast, influenza B viruses (IBV) and
influenza C viruses (ICV) reside primarily in human host, although sporadically
infections of other species have been reported (Nedland et al., 2018; Salem et al.,
2017). Influenza D viruses (IDV) have recently emerged in swine and cattle
populations in North America and Eurasia (Chiara et al., 2016; Collin et al., 2015;
Ducatez et al., 2015; Hause et al., 2013; Luo et al., 2017; Shin et al., 2016; Zhai
et al., 2017). Serological evidences of spillover IDV infections in humans, horses,
and small ruminants have been reported (Hause et al., 2013; Nedland et al.,
2018; Quast et al., 2015; Salem et al., 2017).
2.3.2 Evolution of IAV
The presence of genetically and antigenically distinct IAV subtypes of HA
and NA allow for rapid viral evolution through the process of antigenic shift, which
is defined as the emergence or reemergence of an influenza subtype in a naïve
host population. There are two major mechanisms that enable IAV evolve and
adapt to new host species: (i) the vRNA genome are segmented, therefore new
strain can emerge through reassortment during co-infection of a cell with two or
more strains; (ii) IAV polymerase complex is responsible for rapid but error-prone
vRNA replication, producing variants of the viral proteins, including the HA and
NA, that potentially cause antigenic or genetic drift (Miotto et al., 2010). IAVs
were found in various vertebrate species, where they form reservoirs that do not
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easily mix. While human IAVs do not spread in birds and vice versa, the species
barrier to pigs is relatively low, so that pigs might function as "mixing vessels" for
the creation of new pandemic reassortants (Nelson & Vincent, 2015).
Phylogenetic studies revealed that about 100 years ago, an avian
influenza A virus had crossed the species barrier, presumably first to pigs, and
from there to humans, forming the new stable human and classical swine
lineages. In 1979, again, an avian virus showed up in the North European swine
population, forming another stable swine lineage. The North European swine
isolates from 1979 until about 1985 were genetically extremely unstable. A
hypothesis is put forward stating that a mutator mutation is necessary to enable
influenza virus to cross the species barrier by providing the new host with
sufficient variants from which it can select the best fitting ones. As long as the
mutator mutation is still present, such a virus should be able to cross the species
barrier a second time, as happened about 100 years ago (Belser & Tumpey,
2018). Although the most recent swine isolates from northern Germany are again
genetically stable, nevertheless, we should be on the alert to watch whether a
North European swine virus shows up in the human population in the near future.
In 1998, a highly virulent H3N2 virus swept across North America.

Genetic

analysis found that this virus was derived from avian, human and swine influenza
viruses and was consequently called triple reassortant H3N2 swine influenza
virus (Ma et al., 2010; Ma et al., 2014). In the following two decades, emerging
new HA and NA genes, and triple reassortant gene constellation (TRIG) from this

14
triple reassortant SIV have synergistically resulted in a rapid explosion of
genetically diverse SIVs (Ma et al., 2010; Ma et al., 2014).
2.3.3 Interspecies transmission of IAV

Figure 3. Interspecies transmission of influenza A viruses
Reservoirs and inter-species transmission events of low pathogenic avian influenza
viruses. Wild birds, domestic birds, pigs, horses, humans and bats maintain their own
influenza A viruses (arrow in circle, subtype in bold). Spill-over events occur occasionally,
most frequently from wild birds (arrow straight, subtype normal font). (Short et al., 2015)
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Interspecies transmission of a virus can lead to a change in the host
tropism of the virus. The change may involve multiple factors. The HA has long
been considered to be the primary determinant of influenza virus host range
determinant. HA binds to cellular glycosylated receptor proteins via their terminal
sialic acid residues. Mutations in the HA may change the receptor-binding
specificity of the IAV and lead to the interspecies transmission. Humans possess
sialic acid bound to galactose in an α2,6 orientation whereas avian receptor
proteins possess α2,3 oriented sialic acid-galactose linkages (Short et al., 2015).
Swine possess both α2,6- and α2,3- linked sialic acids, leading to their
designation as “mixing vessels” for influenza viruses. On the other hand, the
diversity of cellular receptors in various species is thought to be a determinant
factor of influenza virus tropism. IBV binds sialic acids linked to galactose in
either α2,6 or α2,3 orientation (Vijaykrishna et al., 2015). In contrast to IAV and
IBV, ICV and IDV bind to 9-O-acetylated sialic acids (Song et al., 2016; Wang &
Veit, 2016).
The primary reservoir for IAV is waterfowl (Figure 3). The virus replicates
primarily in gut tissues in these birds but rarely causes disease. Low level of
genetic mutation rate and low pathology in waterfowl infected with IAV suggest
that IAV has reached evolutionary stasis in these species. Sixteen HA (HA1-16)
and nine NA (NA1-9) subtypes are found in aquatic avian species, however a
recent study characterizing an IAV from bats in Central America found novel HA
and NA subtypes (Joseph et al., 2017).

IAV also infect a wide variety of
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mammals but host susceptibility is usually limited to relatively few HA and NA
subtypes (Figure 3) (Joseph et al., 2017; Short et al., 2015).
Unlike IBV and ICV that rarely transmit across species, sustained inter
species transmission of IAV has been demonstrated (Joseph et al., 2017; Short et
al., 2015). IAV are unique among the Orthomyxoviridae in that they possess
numerous subtypes that co-circulate. This allows for rapid antigenic shift, resulted
by co-infection and reassortment of multiple IAV strains from different subtypes.
Reassortment is frequently seen in SIV. There are numerous subtypes and
lineages of IAV co-circulating in pigs (Palese & Wang, 2011). From the first
isolation of swine influenza virus in 1930 until 1998, there was very little diversity
in SIV. H1N1 viruses dominated swine influenza until the 1990’s when H3N2
viruses also became prominent (Vincent et al., 2008).

In 1998, a triple

reassortant H3N2 virus consisting of avian, human and swine influenza virus
segments was identified in pigs that was associated with severe clinical disease
(Olson & Dinerstein, 2002). The triple reassortment gene constellation (TRIG)
was rapidly disseminated through the North American swineherd, replacing the
previous wholly-swine influenza viruses. The 2009 pdmH1N1 was another
example of reassortment related to SIV. These changed strains have
successfully crossed tropism barriers and become endemic to new host
populations.
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2.4

Host Immunity and Immune Evasion of Influenza Viruses
Upon detection of IAV infection, host immune system is activated to

defend against the viral infection. Innate immune response is the first line of
defense against viral infection. The adaptive immunity, mediated by B cells and T
cells, will recognize, fight and eliminate pathogens. On the other hand, IAVs have
utilized multiple ways to escape from host immunity.
2.4.1 Innate immunity against IAV infection
Innate immunity is the first line of defense against pathogens. During the
IAV infection, the conserved components called pathogen associated molecular
patterns (PAMPs) are recognized by host pathogen recognition receptors
(PRRs). These PAMPs have certain characteristic of viral RNA that are not
shared by cellular RNAs, such as regions of double-stranded RNA (dsRNA) or
the presence of a 5’-triphosphate group. Retinoic acid-inducible gene-I protein
(RIG-I) and toll-like receptor (TLR) are well-known PRRs for IAV (Gack, 2014;
Lee et al., 2013).

The activation of the signaling pathways induces the

production of various cytokines and antiviral molecules.
RIG-I like receptors (RIG-I, MDA5, and LGP2) are characterized by a
conserved domain structure, consisting of a central DExD/H-box helicase domain
and a C-terminal domain (CTD), both of which are responsible for binding viral
RNA.

The RIG-I like receptors (RLRs) recognizes the intracellular non-self

ssRNA and transcriptional intermediates of IAVs in the infected host cells.
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Following the recognition of PAMPs, RLR is activated and its caspase activation
and recruitment domain (CARD) is modified. This triggers the downstream
transduction signaling at the outer mitochondrial membrane (Gack, 2014).
Subsequently, downstream signaling pathways are activated, leading to type I
IFN gene expression (Gack, 2014).
Toll‐like receptors (TLRs) are pattern recognition receptors expressed by
the antigen‐presenting dendritic cells, monocytes/macrophages, and epithelial
cells, which trigger the innate immune responses against invading pathogens
(Lee et al., 2013). The endosomal TLRs can detect viral nucleic acids (dsRNA,
ssRNA, CpG oligodeoxynucleotides). Recent in vitro and in vivo studies on
influenza pathogenesis have shown that TLR activation induces expression of
type I interferon and pro‐inflammatory cytokines (e.g., IL‐6, TNF‐α), thereby
limiting viral replication and dissemination, mediating tissue inflammation. These
cytokines will facilitate the development and maturation of adaptive immunity.
Animal studies showed that TLR ligands may rapidly up regulate the innate
immunity to provide broad‐range, virus strain non‐specific protection against
lethal influenza challenge (Lee et al., 2013).
2.4.2 Adaptive immunity against IAV infection
The second line of defense against infection is the adaptive immune
response, which consists of humoral and cellular immunity. Adaptive immunity is
relatively slow but specific upon the first time infection. The formation of
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immunological memory of the adaptive immunity enables faster and stronger
response after a second infection with the same pathogen.
2.4.2.1 Humoral immunity
IAV infection induces the production of IAV-specific antibodies by B cells.
Antibodies react to the HA and NA largely correlate with protective immunity.
Antibodies binding to the receptor-binding site on the trimeric globular head
region of HA can confer neutralizing immunity to IAV infection. The neutralizing
antibodies can block virus attachment to host cells and subsequently block
receptor-mediated endocytosis (Air, 2015). However, the HA globular head (see
section 2.5 below) is highly variable, as a result, most antibodies directed against
HA are influenza virus strain-specific and fail to neutralize antigen drift variants
and viruses of other subtypes (Yu et al., 2008). Humoral immunity provides longlasting antibody mediated protection against the strains that antigenetically
resemble the infected strain. Of interest, broadly reacting antibodies directed
against the conserved stem region of HA have been identified (Wang et al.,
2010b; Wang et al., 2010c).
Antibodies react to sialydase NA, which release budding virus from
infected cells, also exert protective immunity. Although NA-specific antibodies are
not neutralizing, i.e. not able to block virus entry and fusion, they are still able to
inhibit the enzymatic activity of NA and therefore limit the viral spread and reduce
virus replication efficiency (Marcelin et al., 2012). In addition, transmembrane
protein M2 plays an important role in uncoating the viral genome in the
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endosome. Protective effect of M2-specific antibodies was demonstrated in
recent studies (Kim et al., 2017; Rappazzo et al., 2016). Furthermore, evidences
indicate that NA-, M2- and NP-specific antibodies may contribute to ADCC
(Vanderven et al., 2017). Since M2 and NP proteins are highly conserved
between various influenza A virus subtypes, the antibodies may confer clearance
to heterosubtype viruses, although their mechanisms of actions are poorly
understood (Vanderven et al., 2017). In addition to serum antibodies, local
mucosal IgA antibodies are important to protect airway epithelial cells from
infection (Rahn et al., 2015).
2.4.2.2 Cellular immunity
Primary T-cell responses are induced when naive T-cells encounter
antigen presented via MHC I or MHC II molecules. During IAV infection, viral
proteins degraded into peptides (8–10 amino acids) that were loaded onto the
HLA molecules and presented to circulating T-cells (Leone et al., 2013). The
presented antigens activate the naive T-cell, which as a result leads to the
proliferation and differentiation of naive T-cells into effector and memory T-cells.
The IAV-specific CD8+ cytotoxic T cells (CTLs) can recognize and eliminate IAVinfected cells through cytokine-directed killing or Fas-FasL mediated killing, thus
preventing the spreading of virus. IAV-specific CD8+ CTL cells predominantly
recognize internal proteins represented by M1 and NP (Jameson et al., 1998).
CD8+ T cells can be classified as Tc2, Tc17, Tc9, and CD8+ Treg cells, in
addition to CTLs. CTL, Tc2 and CD8+ Treg cells have a strong cytotoxic function,

21
which is in contrast to Tc9 and Tc17 cells with a low cytotoxic function (Huber &
Lohoff, 2015). However, Tc17 cells were demonstrated to provide protection to
influenza virus infection (Hamada et al., 2009). CD4+ T-cells have been
demonstrated to directly kill virally infected cells (Topham & Doherty, 1998). In
addition, CD4+ T-cells can provide help to CD8+T-cells. CD4+ T cells also play
an important role in humoral immunity (Jameson et al., 1998). After IAV infection,
variant IAV-specific memory T-cell populations are established that may enable
the host adaptive immune system rapidly respond to future infection (Jameson et
al., 1998).
2.4.3. Escape of innate and adaptive immunity
IAV adopts various strategies to evade immunity. Binding of influenza viral
proteins to various components of the innate immune system leads to their
inhibition. Firstly, the NS1 protein is the major player to antagonize the antiviral
innate immune response. NS1 inhibits RIG-I receptor signaling by various
means. It blocks transcriptional activation of the IFN-β promoter (van de Sandt et
al., 2012). Other than NS1, PB2 and PB1-F2 can reduce the IFN-β induction.
Viral polymerase complex, consisting of PB2, PB1 and PA, is also involved in
cap-snatching of host mRNAs and thereby reduces host cell gene expression
including that of IFN-β. The encapsidation of vRNA by NP proteins is likely to
reduce the formation of dsRNA, which could otherwise lead to activation of RIG-1
signaling (van de Sandt et al., 2012).
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A combination of immune pressure in the human population and the high
mutation rate of the influenza A virus leads to new IAVs that can escape the
existing adaptive humoral and cellular immune responses. Due to the lack of
proofreading activity, the transcription of viral RNA by the viral RNA polymerase
is error prone and results in nucleotide changes and amino acid changes, that
can reduce effectiveness of recognition of antibody as well as CTL epitopes.
Antigen shift is another mechanism IAV use to escape humoral immunity and
CTL responses (Johnson et al., 2017; Shao et al., 2017).

2.5

Influenza hemagglutinin structure biology and Universal Vaccine

2.5.1 Receptor binding specificity of HA (HEF) and host tropism
HA homotrimer forms spikes on the viral envelope. These spikes of HA
bind to sialic acid on the surface of the host cell’s membrane. The HA precursor,
HA0, is made up of two subunits: HA1, which contains the receptor binding
domain, and HA2, which contains the fusion peptide. The detailed structure and
function of HA protein has been described in detailed in Chapter 4 below. Two
major linkages are found between sialic acids and the glycan to which they are
bound: α2,3 and α2,6. These are extremely important for the specificity of the HA
molecules in binding to cell surface sialic acid receptors found in different
species. Viruses from humans recognize the α2,6 linkage, whereas those from
avian and equine recognize the α2,3 linkages. Those from swine recognize both.
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This explains the importance of swine being a good mixing vessel for avian and
human influenza viruses, hence producing dangerous pathogenic viruses (Samji,
2009). Interestingly, functionally important and conserved sequences in HA, such
as the fusion peptide, are buried inside and not accessible for antibody
recognition. HA2 stem domain is also relatively conserved when compared to
HA1 globular receptor binding domain. These conserved domains or regions in
the HA2 are good target for vaccine development toward a universal protection.
2.5.2 Current IAV Vaccines
Currently most used seasonal influenza vaccines are egg-based,
inactivated vaccines. More recently, FDA also approved cell-based vaccines and
recombinant vaccines. Both trivalent and quadrivalent vaccines are made to
increase the protection range (FDA, 2018). The IAV strains are selected
according to recent epidemics. Although these vaccines are considered safe and
efficacious, which are closely matched to circulating strains, infamous antigenic
drift of influenza viruses under natural evolution or through egg culture enable the
viruses to escape the neutralizing activity of antibodies induced by vaccination.
Another issue is that the current vaccines usually fail to provide long-term
protection and therefore require annual administration. Finally, in the event of a
pandemic outbreak, the time consuming production of a new pandemic influenza
vaccine is another concern. Seasonal influenza vaccines do not offer good
protection against pandemic strains of novel subtypes due to the mismatch of
humoral and cellular immune responses.
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2.5.3 Universal IAV vaccine
One target of universal IAV vaccine is M2 protein. A number of vaccine
studies using the extracellular domain of M2 (M2e) as an immunogen have
demonstrated that M2e vaccines can offer protection against lethal challenge by
some different subtypes in mice and ferrets. These M2e vaccines reduced viral
shedding in the lower respiratory tracts of these animals (Deng et al., 2015). The
protection against lethal challenge in mice could also be achieved by passive
transfer with monkey sera containing high M2e antibody titers (Deng et al.,
2015). Human clinical trials for testing M2e vaccine efficacy are currently being
conducted (Schotsaert et al., 2009). M2e-specific antibody enhancement in pigs
may suggest that caution should be exercised when using M2e vaccination in
humans. Please note that efforts toward exploring viral fusion machinery as a
universal vaccine target has been described in Chapter 4 below.
2.5.4 IAV Reverse Genetics and vaccine development
Over the past several decades, one most important progress in influenza
research field is the development of numerous robust reverse genetics systems.
With this system, researchers around the globe can study functions of encoded
viral proteins and non-coding elements of viral genomes. Also various forms of
influenza vaccines have been developed due to influenza reverse genetics
system (Nogales & Martinez-Sobrido, 2016). Influenza virus contains segmented
RNA genomes in a negative sense. So conversion of these unstable RNA into
stable DNA through RT-PCR and placing them in the context of both polymerase
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I and II promoters so both vRNA and mRNA molecules corresponding each
individual can be generated, which is the technical foundation of influenza
reverse genetics system.

This dissertation especially in Chapter 4 has

harnessed influenza reverse genetics system to study structure-function of the Bloop and CD helix. A reverse genetics recovered attenuated virus has been
advanced to a pilot trial in pigs to evaluate its vaccine efficacy against both H1N1
and H3N2 subtypes.
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CHAPTER 3. DETAILED MAPPING OF THE LINEAR B CELL EPITOPES OF
THE HEMAGGLUTININ (HA) PROTEIN OF INFLUENZA H1N1PDM09 VIRUS
BY USING SYNTHETIC PEPTIDE ARRAY APPROACH

3.0

Abstract
We presented here a detailed analysis of the antigenic determinants of the

Hemagglutinin (HA) protein of pdm09 strain (subtype H1N1) by the HA peptide
array in Enzyme-linked immunosorbent assay (ELISA) with immune serum from
experimental infected pigs by swine influenza A viruses (SIVs). The peptide array
contains 139 peptides spanning the HA protein of H1N1pdm09 and peptides are
14- or 15-mers with 11 amino acid overlaps. A panel of swine antisera against
SIV H1 clusters α, β, γ, δ-A, δ-B, H1N1pdm09, and H3 cluster was used in this
study and SIVs used for swine hyperimmune sera production are representative
subtypes and clusters of SIV circulating in North America. The results of these
studies identified three immunedominant peptides, one located in the HA1
(amino acids 57-71) and two in the HA2 (amino acids 481-495, and 553-566),
reactive to its homologous antisera (H1N1pdm09). Analysis of peptide reactivity
with heterologous serum samples revealed that antibody responses to two HA2
peptides (amino acids 481-495 and 553-566) are completely conserved among
antisera of all H1 clusters. In addition to H1N1pdm09, HA1 peptide (amino acids
57-71) was reactive to SIV H1 γ antisera. Interestingly, none of peptides in HA
peptide array of H1N1pdm09 were reactive to SIV H3 antisera, despite that this
antisera has a HI antibody titer similar to those of H1 clusters antisera. Structural

27
modeling localized two conserved immunodominant determinants to the
membrane proximal external region (MPER) (amino acids 481-495) and the
intracytoplasmic tail (amino acids 553-566) of the HA molecule. Finally,
intranasal inoculation of peptides 15 and 121 into pigs revealed that peptide 121,
not peptide 15, was able to generate antibody responses in some animals. These
antigenic analyses provide an important foundation for further analyzing the
immune response against these peptides during natural SIV infections and also
provide potential peptide substrates for diagnostic assays and for vaccine
strategies.
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3.1

Introduction
Swine influenza is caused by swine influenza A virus (SIV), which belongs

to the Orthomyxoviridae family (Easterday, 1980). The pathogen is an important
component of the porcine respiratory disease complex and by itself can have a
significant impact in the swine industry (Vincent et al., 2008). An additional
concern regarding SIV, is its zoonotic potential, as under certain circumstances,
it can be transmitted to humans, which is best exemplified by 2009 H1N1
pandemic originated from swine source (Maines et al., 2009).

Recently,

transmissions of variant swine H3N2 virus (H3N2v) to humans have also been
documented (Wong et al., 2013).
A typical outbreak of respiratory disease caused by SIV is characterized
by sudden onset, and rapid spread within a herd. Clinical symptoms associated
with swine influenza may include coughing, sneezing, nasal discharge, elevated
rectal temperature, lethargy, breathing difficulty, and depressed appetite
(Easterday, 1980; Vincent et al., 2008). While morbidity rates may reach 100%
with SIV infections, mortality rates are generally low.
The genome of SIV is separated into 8 independently RNA segments at
the negative-sense that allows for frequent reassortment when two different
viruses infect and replicate within the same cell of a pig. Reassortment event
often results in the production of new influenza virus (antigenic shift), which
renders the current strain-specific vaccine strategy ineffective.

In addition,

influenza A virus has the unique capacity to undergo genetic variations (antigenic
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drift) by being able to mutate up to 50% of the amino acid sequence of its major
surface protein, hemagglutinin (HA), without changing the function of the HA.
Both antigenic drift and antigenic shift contribute to apparent failures of swine
influenza vaccines when used in swine industry.
In the United States, SIV H1N1, H1N2, and H3N2 subtypes have emerged
as the major causes of swine influenza, although two other subtypes of SIV
(H3N1 and H2N3) have also been isolated from the diseased pigs on some
occasions (Rajao et al., 2018). Each subtype consists of numerous lineages or
clades and these lineages of swine influenza virus circulate concurrently in pigs,
which present a challenge to effective control and prevent of this important
disease (Rajao et al., 2018).
The aim of this study was to determine the antigenic determinants of the
hemagglutinin (HA) protein of swine H1N1 pandemic 2009 virus (H1N1
pdm09) by using the HA peptide array in Enzyme-linked immunosorbent assay
coupled with immune serum from experimental infected pigs by SIVs. The
peptide array contains 139 peptides spanning the HA protein of H1N1pdm09 and
peptides are 14- or 15-mers with 11 amino acid overlaps. A panel of swine
antisera against SIV H1 clusters α, β, γ, δ-A, δ-B, H1N1pdm09, and H3 cluster
were used in this study (Hause et al., 2010; Lorusso et al., 2011). Our
experiments identified two conserved peptide antigens (peptides 121 and 139)
located in HA2 that were reactive to all tested SIV H1 antisera. In addition,
peptide 15 in HA1 was recognized by a subset of H1 antisera. Interestingly, none
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of these identified peptides were recognized by SIV H3 reference antisera. The
results of our experiments shall provide an important foundation for further
analyzing the immune response against these peptides during natural SIV
infections and also provide potential peptide substrates for design of diagnostic
assays and vaccine strategies against influenza A virus infection of swine.

3.2

Materials and Methods

3.2.1 Peptide array
Peptide array is derived from the hemagglutinin (HA) protein of Influenza
Virus A/California/04/2009 (H1N1)pdm09 with swine origin, which was obtained
through BEI Resources, NIAID, NIH (Cat# NR-15433). This is a 139-peptide
array that spans the whole HA protein. Peptides are 14- to 15-mers, with 11
amino acid overlaps. Each peptide was dissolved with Dimethyl sulfoxide
(DMSO) (Sigma-Aldrich) at a concentration of 1 mg/ml.
3.2.2 Pig sera.
A previously described standard panel of porcine immune sera collected
from experimentally inoculated pigs was used in this study (Hause et al., 2010).
Three-week-old SIV-negative pigs were obtained from a commercial vendor.
Groups of 3 pigs were used for antisera generation against a panel of swine
influenza virus reference isolates, including H1 clusters (α, β, γ, δ-A, δ-B,
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H1N1pdm09) and a H3 cluster. Each of these viruses was propagated in ST cells
(reaching to 1280 to 2560 hemagglutination units per ml) followed by the
inactivation with 5 mM binary ethyleneimine (BEI) (Sigma-Aldrich) for 24 hours at
37ºC. After formulation with Trigen, a proprietary adjuvant (Newport Laboratories,
Worthington, Minnesota), each of these viral antigens was inoculated into a
group of three pigs (2 ml each pig) on days 0, 7, 14, and 21 intramuscularly. Sera
were collected and pooled on days 0 and 35, respectively, prior to testing.
Because sera collected from inoculated pigs had very high HI titers (homologous
HI 1280 to > 20,480), sera were diluted four-fold to 16-fold in serum collected
from cesarean-derived, colostrum-deprived pigs to achieve homologous HI titers
of 1280. The diluted reference antisera stocks were aliquoted and frozen at 80ºC. In addition, we generated negative control sera by injecting pigs with ST
cell debris and adjuvant. Sera generated from the ST cell debris were not diluted.
No immune pig sera obtained from 50 pigs known to be free from swine influenza
exposure and infection (negative for IAV-specific by ELISA were used as
negative control sera to detect background immunoglobulin binding in peptide
ELISAs.
3.2.3 Peptide ELISA.
Flat bottom 96-well plates were coated with each of the synthetic HA
peptides (100 μl/ 0.5μg each well) in coating buffer (10 mM NaHCO3 buffer, pH
9.6) for overnight incubation at 4°C. After washing five times (300 μl/well) with
PBST wash buffer (PBS with Tween 20), plates were blocked with blocking buffer
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(PBST containing 0.2% gelatin) for 2 hours at 37°C followed by additional
washing.

Then 100 μl of diluted serum samples (1:300 in PBST containing

0.01% gelatin) was added to each well and incubated at 37°C for 1 hour.
Following five times washing, antibody binding was detected by incubation with
100 µL of goat anti-swine IgG-HRP conjugates (SeraCare) diluted 1∶2000 in
blocking buffer at 37°C for 30 min. The calorimetric reaction, indicative of the
presence of bound antibody, was mediated by the addition of 100 µL freshly
prepared tetramethylbenzidine (TMB) substrate solution (SeraCare). The
reaction was stopped by addition of 50 µL of 4 M sulfuric acid and the optical
density (OD) was measured at 450 nm in an ELISA microplate reader (BioTek).
The 50 negative control sera coupled with randomly selected 4 peptide
pools (each peptide pool consisting of five sequentially overlapping peptides)
were used to determine the cut-off value of the peptide ELISA, which was equal
to the mean OD of the negative samples plus 3 standard deviations. The derived
positive cut-off value of 0.18 or greater was used to determine whether a given
SIV cluster-specific serum had positive serological reactivity to the peptides. To
reduce the background (BG) noise reaction caused by the hydrophobic binding of
immunoglobulin and immune-complexes in pig sera to plastic surfaces, all the
OD values obtained in peptide(s)-coated wells were subtracted from the BG OD
values in peptide(s)-uncoated wells.
3.2.4 Hemagglutination inhibition (HI) assay.
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HI assays were performed following standard procedures (Hause et al.,
2012). In brief, sera were treated with a receptor-destroying enzyme for 24 h at
37°C and then adsorbed with a 20% suspension of turkey erythrocytes in
phosphate-buffered saline (PBS) for 30 min at room temperature. Virus
suspensions containing 4 to 8 HA units of virus were incubated for 1 h with serial
2-fold dilutions of antiserum, and the HI titer was determined as the reciprocal of
the highest dilution that showed complete inhibition of hemagglutination using
0.5% washed turkey erythrocytes.
3.2.5 Virus neutralization assay.
Virus neutralization assays were performed as previously described (Ran
et al., 2015), with slight modifications. Two-fold serial dilutions in PBS, from 1:4
to 1:32,768, were performed on the sera. Next, 100 μl of 40 to 200 median tissue
culture infective doses (TCID50)/100 μl of virus was added to each serum dilution
and incubated for 1 h at 37°C in 5% CO2. The serum-virus mixture was next
transferred to a confluent monolayer of MDCK cells and incubated at 37°C in 5%
CO2 for 4 days. Viral neutralization was assessed by a lack of cytopathic effects
in each well by microscopy. Back titrations were performed on MDCK cells to
confirm a virus concentration of 40 to 200 TCID50/100 μl.
3.2.6 Structural locations of peptides tested positive in ELISA.
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The Hemagglutinin structure (PDB 3LZG) from H1N1 pdm09 that derives
the HA peptide array was chosen as the template to locate ELISA-positive
peptides in the context of the HA structure.

3.2.7 Sequence logos.
We used pLogo software (http://rth.dk/resources/plogo/) to determine the
sequence conservation of the identified B-cell linear epitopes. For this purpose,
we analyzed all available SIV cluster-specific full-length HA protein sequences of
swine influenza A virus strains that circulated between 2006 to 2015 in pigs
farms of the United States.

Sequence logo provides better description of

sequence conservation than consensus sequences and can reveal significantly
structural and functional features of the identified epitopes. Each logo consists of
stacks of letters (amino acids), one stack for each position in the sequence. The
overall height of each stack indicates the sequence conservation at that position
(measured in bits), whereas the height of symbols within the stack reflects the
relative frequency of the corresponding amino acid at that position. The residue
position in the block is shown on the X-axis, and the information content is shown
on the Y-axis. The default color scheme displaying different amino acids
according to their different chemical properties is as follows: polar amino acids
(G, S, T, Y, C, Q, N) colored with green, basic (K, R, H) with blue, acidic (D, E)
with red, and hydrophobic (A, V, L, I, P, W, F, M) amino acids with black.
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3.2.8 In vivo evaluation of immunogenicity of peptides 15 and 121.
3-week-old commercial influenza antibody-negative pigs were obtained
from a commercial vendor in Minnesota. The pigs were acclimatized for 7 days
before inoculation of peptide immunogens. Maintenance of pigs and all
experimental procedures were conducted in accordance with the guidelines of
the Institutional Laboratory Animal Care and Use Committee, South Dakota State
University. Peptide antigens were conjugated with carrier protein KLH (500µg of
peptide dissolved in total volume of 1ml PBS). Each of six 4-week-old influenza
antibody-negative commercial pigs were inoculated intranasally with one ml
suspension of the KLH-conjugated peptide 15 and 121 along with heat labile
enterotoxin (25 µg LT), while each of 4 control pigs received 1 ml PBS each
intranasally. Two weeks later, all piglets received a booster dosage. Blood
samples were collected for the serum isolation via the jugular vein from piglets 2
weeks after the second round of immunization. Serum samples were also
obtained by the same method prior to immunization. Peptide-specific antibodies
were measured in the ELISA assay as described above.

3.3

Results

3.3.1 Identification of HA peptide pools reactive to SIV H1N1pdm09 reference
serum.
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To localize linear B-cell epitopes of the hemagglutinin (HA) protein of
H1N1 pdm09 in swine, the pig H1N1pdm09 serum was reacted against the
peptide array derived H1N1 pdm09 and analyzed for specific antibody binding.
We first screened antibody reactivity against peptide pools in the ELISA and
each peptide contained five sequentially overlapping peptides that were arranged
from the N-terminal end of the HA protein. Three out of the twenty-eight peptide
pools were tested positively against H1N1pdm09 antisera (Figure 4).
Table 3. Summary of positive peptide pools identified in ELISA using swine
antisera against H1N1 pdm09 virus.

Note: “-” sign indicates that peptide pools are not reactive to swine antisera
raised against homologous H1N1 pdm09 virus (i.e., OD values less than the
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ELISA cut-off 0.18). Positive peptide pools are indicated with red font color.
Sequences with yellow shades are located in HA1. Sequences with blue shades
are located in HA2. Junction sequence between HA1 and HA2 are not shaded.
Reported OD data represent average background-corrected OD values obtained
from three independent experiments, each assayed in duplicate. See Materials
and methods section for details.

3.3.2 Identification of individual peptides recognized by SIV H1N1pdm09
reference serum.
To further determine individual peptide epitopes from the above positive
peptide pools, each peptide was tested against H1N1pdm09 antisera in the
peptide ELISA under similar experimental conditions. The reactivity pattern was
as follow: peptide 15 from the positive peptide pool 11-15 reacted strongly with
antisera; similarly, peptide 121 from the positive peptide pool 121-125 was
recognized by H1N1pdm 09 antisera; interestingly, three overlapping peptides
137, 138, and 139 all reacted with antisera. Significantly, the observation of an
immunodominant porcine B cell epitope represented by peptide 15 is in
agreement

with

an

early

study

demonstrating

that

this

peptide

was

immunoreactive against convalescent sera from H1N1pdm09 patients (Zhao et
al., 2011). Porcine B cell epitopes represented by peptides 121, 137, 138, and
139 have not reported previously in the context of human infection by
H1N1pdm09 virus.

38
Table 4. Individual peptides reactive to swine antisera against H1N1 pdm09
virus
Peptide OD

Sequence

15

0.662

57 KLCKLRGVAPLHLGK 71

121

0.262

481 CFEFYHKCDNTCMES 495

137

1.101

545 VSLGAISFWMCSNGS 559

138

1.426

549 AISFWMCSNGSLQCR 563

139

0.636

553 WMCSNGSLQCRICI 566

Note: The underlined amino acid residues for peptides 137, 138, and 139 are
those shared among three reactive peptides. Reported OD data represent
average background-corrected OD values obtained from three independent
experiments, each assayed in duplicate. See Materials and methods section for
details.
3.3.3 Structural locations of positive peptides.
Peptide 15 (residues 57 to 71) is located in the HA1 subunit, while peptide
121 (residues 481 to 495) is located in the HA2 region. These two peptides are in
the HA ectodomain. In contrast, peptides 137 (residues 545 to 559), 138
(residues 549 to 563), and 139 (residues 553 to 566) are within the
transmembrane (TM) domain and cytoplasmic tail of HA.

To visualize the

location of the peptides on the HA protein, we mapped the peptides on the
resolved pdm09 HA’s ectodomain structure (Fig. 4). Peptide 15 comprises of a
mixture of loop and ß–sheet conformations, which links the stem and the globular
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domains and is largely surface exposed. Peptide 121 containing a mixture of αhelix, loop, and ß–sheet is located in close proximity to the transmembrane
region with the helical region fully exposed to the surface. The surface-exposed
nature of peptides 15 and 121 may make their corresponding antibodies bind to
the virions so antibody binding may have an effect on viral replication.
Visualization of three other peptides (peptides 137, 138, and 139) could not been
performed due to the unavailable structure of HA’s transmembrane region and
cytoplasmic tail.
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HA1

Pep15

HA2

Pep121

Figure 4. Locations of reactive peptides in the context of the hemagglutinin
(HA) structure (PDB 3LZG) of H1N1 pdm09 virus.
The Hemagglutinin structure (PDB 3LZG) from H1N1 pdm09 that derives the HA
peptide array was chosen as the template to locate ELISA-positive peptides in
the context of the HA structure. Peptides 15 and 121 are colored with light green
and dark blue, respectively.
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3.3.4 Cross reactivity of peptides to reference sera representing different H1
clusters/subtypes of SIV.
We next determined whether pig reference sera, representative of
different H1 clusters and H3 subtype of SIV, recognized the identified peptides.
For this experiment, we focused on peptides 15, 121, and 139. Peptides 137
and 138 were not further evaluated because peptide 139 significantly overlaps
with peptides 137/138 and peptide 139-derived data may be viewed as a
representative of these three overlapping peptides. In addition, all reference sera
used in this study were uniformly diluted into same HAI antibody titer 1:1280
against the virus that was used to generate these sera. Figure 5 summarizes the
serological cross-reactivity of these peptides. Peptide 139 was highly reactive to
all tested SIV H1 antisera, while peptide 121 was moderately reactive to all these
sera. The strong relative inter-cluster reactivity (immunodominant) demonstrated
with peptide 139 and the weak cross-reactivity (immunoreactive) noted with
peptide 121 concurs with the results obtained with the reference pdm09 serum
(Tables 3 and 4). Furthermore, in addition to H1N1 pdm09 reference serum,
peptide 15 was weakly reactive to H1 γ serum. Significantly, none of these three
peptides were recognized by SIV H3 antisera, despite that this serum has a HAI
antibody titer similar to those of H1 clusters antisera. Three peptides displayed
no antibody binding activity with the reference SIV antibody serum.
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Figure 5. Recognition of three positive peptides by swine antisera raised
against different clusters of swine H1N1 and a H3N2 subtype.
Each of three peptides (15. 121, and 139) was used to coat 96-well plate. Swine
antisera (1:300) from indicated H1 and H3 clusters of swine influenza were
examined for the presence of antibodies to these three peptides using ELISA as
detailed in materials and methods section. The background-corrected OD values
of antisera for each peptide are calculated and plotted. The data presented in this
figure are representative of three independent experiments, each assayed in
duplicate.
3.3.5 Conservation analysis of the identified linear peptide epitopes in different
H1 clusters and H3 subtype of swine influenza A viruses.
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We used sequence logos (O'Shea et al., 2013) to visualize the
conservation of individual amino acids within each identified epitope, with the
height of each letter indicating the proportion of sequences that contain the
residue at that site (Figure 6). Sequence of peptide 139 (WMCSNGSLQCRICI) is
completely identical among all H1 clusters except for δ-B (Delta2) cluster. The
vast majority (90%) of Delta2 strains have an arginine (R) at position 563 (R563),
which is akin to SIV H1 strains in other clusters, while another 10% have a
closely related lysine substitution (K563). This substitution seems not affecting
the recognition of peptide 139 by Delta2 antisera. In contrast, 6 positions in the
corresponding amino acid sequences of SIV H3 strains are occupied by different
amino acids. Epitope conservation analysis of peptide 139 supports its universal
recognition by all tested H1 cluster serum, not by a H3 subtype sera. Peptide 121
(CFEFYHKCDNTCMES) is highly conserved among all H1 clusters. Amino acid
variations in this epitope are centered on positions 489, 490, and 491. For
example, all strains of cluster alpha have an alanine (A) at position 491, while all
strains of Beta and 99% of Gamma strains have a closely related threonine
substitution (T491). Interestingly, Glutamic acid (E) occupies this position at
Delat1 and Delat2 strains. Changes at these three positions have no substantial
effects on the universal recognition of peptide 121 by antiserum of H1 clusters.
Analysis also showed that SIV H3 strains differed from H1 strains by 8 positions
in the corresponding region and this significant variation in the epitope may
explain why peptide 121 is not recognized by SIV H3 antisera. Analysis of the
sequence similarity in peptide 15 (KLCKLRGVAPLHLGK) displayed by various
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H1 clusters also supported a relation between epitope sequence conservation
and antibody recognition.

In addition to homologous sera (pdm09 H1N1),

antisera generated against Gamma cluster (pdm09 belongs to this cluster) also
recognized peptide 15. P15 peptide sequence is completely conserved among all
analyzed strains of Gamma cluster. Interestingly, antiserum generated against
other clusters of SIV subtype H1 and a H3 subtype strain failed to be reactive to
this epitope due to multiple changes in the region.
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Figure 6. Conservation of identified peptide epitopes among swine
influenza A H1N1 and H3N2 viruses.
Logo analysis is shown for the frequency of each amino acids within each of
three peptides in swine influenza strains from indicated H1 clusters and H3 that
circulated between 2006 to 2015 in pigs farms of the United States. The height of
the letter indicates the frequency of individual amino acid residue at that site. The
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residue position in the block is shown on the X-axis, and the information content
is shown on the Y-axis. The default color scheme displaying different amino
acids according to their different chemical properties is as follows: polar amino
acids (G, S, T, Y, C, Q, N) colored with green, basic (K, R, H) with blue, acidic
(D, E) with red, and hydrophobic (A, V, L, I, P, W, F, M) amino acids with black.
3.3.6 Evaluation of immunogenicity of peptides 15 and 121 in pigs.
We finally determine the immunogenicity of the identified B cell epitopes
displayed in peptides 15 and 121. Peptide 139 is not selected for this study
because this peptide is not exposed in the HA protein surface and may not
constitute a target for protective antibody response.
Peptide antigens containing peptides 15 and 121 were conjugated with
carrier protein KLH (500µg of each peptide dissolved in total volume of 1ml PBS).
Each of six 4-week-old influenza antibody-negative commercial pigs was
inoculated intranasally with one ml suspension of the KLH-conjugated peptide 15
and 121 along with heat labile enterotoxin (25 µg LT), while control group
containing four pigs received 1 ml PBS each intranasally. Two weeks later, all
piglets received a booster dosage. Blood samples were collected for the serum
isolation via the jugular vein from piglets 2 weeks after the second round of
immunization. Peptide-specific antibodies were measured in the ELISA assay as
described above. As summarized in Figures 7 and 8, 2 out of 6 inoculated pigs
showed detectable antibodies against peptide 121 at six weeks following the
immunization (Figure. 7). All inoculated pigs, however, were found negative in
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antibody response to peptide 15 during the course of this study (Figure 8). Taken
together, peptide 121 appears to be immunogenic to pigs; despite that the
antibody response elicited by this peptide is not uniform among inoculated pigs.

Figure 7. Antibody responses against peptide 121 in pigs.
Pig sera collected at the date of inoculation and 6 weeks post-inoculation of KLHconjugated peptides 15 and 121 or PBS were examined by ELISA for their ability
to bind to peptide 121 antigen as described in details in materials and methods
section. The horizontal broken line represents the OD cut-off value. Backgroundcorrected OD values above this line are seropositive for peptide antigen. The
data presented in this figure are representative of three independent
experiments, each assayed in duplicate.
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Figure 8. Antibody responses against peptide 15 in pigs.
Pig sera collected at the date of inoculation and 6 weeks post-inoculation of KLHconjugated peptides 15 and 121 or PBS were examined by ELISA for their ability
to bind to peptide 15 antigen as described in details in materials and methods
section. The horizontal broken line represents the OD cut-off value. Backgroundcorrected OD values above this line are seropositive for peptide antigen. The
data presented in this figure are representative of three independent
experiments, each assayed in duplicate.

3.4

Discussion
A limitation of the peptide array-based approach is that it cannot identify

discontinuous conformation-dependent epitopes that may in fact represent
important antigenic determinants of the HA protein of swine-originated influenza
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H1N1pdm09 virus. This approach, however, has been extensively used to
determine B-cell linear epitopes in viral glycoproteins of several enveloped
viruses including human immunodeficiency virus (HIV), equine infectious anemia
virus (a lentivirus), and influenza A virus (Ball et al., 1992; Forsstrom et al., 2015;
Neurath et al., 1990; Prabakaran et al., 2009; Zhao et al., 2011; Zhou et al.,
2014). The effectiveness of this approach in the identification of specific B-cell
linear epitopes that are immunogenic in the native protein antigen may be
influenced by three major factors. First, the structural and biophysical properties
of a short protein fragment displayed between the isolated peptide and the native
protein may be variable, which may lead to differential antibody binding to the
target. Second, the major histocompatibility complex polymorphisms present in
an outbred population may influence the recognition of a particular peptide
antigen by antibodies. Third, host variability may play a role in generation of
differential activities of host-specific antibodies to same B-cell epitopes.
In this study, we used a synthetic peptide array covering the complete
sequence of the HA protein of swine-originated influenza H1N1pdm09 virus to
map distinct B-cell epitopes reactive with experimentally infected porcine immune
sera. The most significant results of this study are the identification of two HA2derived peptides (peptide 121 and 139) universally reactive to all tested SIV H1
cluster sera. Of these two peptides, peptide 139, located in the HA’s
intracytoplasmic tail, is highly reactive B cell linear determinant. In addition to
peptide 121, another surface-exposed epitope represented by peptide 15 also
emerged but this B cell epitope differs from peptide 121 in that it is only
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recognized by a limited number of H1 cluster serums. It is intriguing to note that
all the identified epitopes fail to be recognized by a H3 subtype serum, indicating
a subtype-specific nature of the identified antigenic determinants. Furthermore,
peptide 121-specific antibodies generated from pigs receiving a mixture of
peptides 15 and 121 are not effective in neutralizing homologous influenza
H1N1pdm09 virus in both hemagglutination inhibition (HI) and virus neutralization
assays (data not shown).
The results of our study reveal several interesting observations. First,
peptide antigen, represented by peptide 139 derived from the intracytoplasmic
tail of the HA protein, is highly immunodominant. This finding is similar to what
have been reported previously in retroviral studies showing that the
intracytoplasmic tail and transmembrane region of retrovirus’s envelope protein is
strongly antigenic determinant (Ball et al., 1992).

Second, a B cell epitope

resided in the peptide 15 has been demonstrated in patients recovered from
influenza H1N1pdm09 infection (Zhao et al., 2011). Despite the similarity, this
early study revealed that this B cell epitope is capable of inducing high titer nonneutralizing antibodies in mice, while our study failed to detect measurable
antibodies against peptide 15 in inoculated pigs. Different adjuvant formulation
used between these two studies may play a significant role in causing this
contrasting outcome. Third, it is unfortunate to observe that antibodies generated
from peptide 121 in pigs possess non-neutralizing capability. It will be interesting
to determine whether peptide 121-specific antibody can protect swine from
influenza A virus infect through other antibody-mediated protective mechanism
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such as antibody-dependent cell-mediated cytotoxicity, which recently emerge as
one of universal influenza vaccine targets. Finally, neither peptides derived the
HA2’s helix A nor peptides from the HA2’s long CD helical domain were tested
positive in pig antisera against various H1 clusters in our ELISA assay. It has
been reported that low antibody titers against the CD region of the HA2 protein
were found in some influenza A viruses-infected patients (Wang et al., 2010b).
These data suggest that using a peptide-based approach to generate antibodies
against two conserved targets (A and CD helices) may run into a challenge in
swine. Considering that antibodies to these regions have a universal protection of
experimental animals against various subtypes, delivery of these targets into
swine for effective induction of such cross-reactive antibodies may seek a
different approach such as expression of these antigens through a nanoparticle
platform.
In summary, we have identified two highly conserved epitopes contained
in peptide peptides 121 and 139 located in HA2 that reacted to all tested SIV H1
antisera. This study also found another epitope in HA1 peptide 15 that was
recognized by a subset of H1 antisera. None of these HA1/HA2 peptides of
H1N1pdm09 were recognized by SIV H3 reference antisera. Results of our study
shall provide an important foundation for further analyzing the immune response
against these peptides during natural SIV infection and also provide potential
peptide substrates for diagnostic assays and for vaccine strategies.
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CHAPTER 4. FUNCTIONAL STUDY OF A ROLE OF N-TERMINAL HA STEM
REGION OF SWINE A INFLUENZA VIRUS IN VIRUS REPLICATION AND
UNIVERSAL SWINE INFLUENZA VACCINE DEVELOPMENT

4.0

Abstract

Swine influenza virus (SIV) is both a pathogen of economical significance to the
swine industry and a potential zoonotic organism that may be transmitted to
humans. A vaccine that can effectively prevent or eliminate the spread of
influenza virus within and between swineherds is urgently needed. We described
here the detailed characterization of a role of N-terminal B-loop and CD helix of
HA2 in swine influenza A virus replication. Results of our experiments
demonstrated that HA protein of swine influenza virus could tolerate some
mutations in functionally conserved B-loop and CD helix. These mutations,
however, have substantially attenuated influenza virus replication in both cell
lines and porcine primary tracheal epithelial cells. Significantly, we found that
some B-loop or CD helix mutations generated virus mutants that replicated in
MDCK and ST cell lines but failed to replicate in primary tracheal epithelial cells,
thereby suggesting that swine HA protein may function as a viral virulence and
pathogenesis factor. Finally, intranasal immunization of attenuated N439G
mutant substantially reduced nasal shedding of both subtypes (H1N1 and H3N2)
in pigs especially at day 5 post challenge. N439G mutation attenuated the virus
replication probably by disrupting the formation of triple CD helix. These data
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demonstrate that intranasal immunization of an attenuated influenza A virus
can limit virus infection and shedding in pigs exposed to homologous H1N1 as
well as heterologous H3N2 subtypes.
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4.1

Introduction
Influenza A virus is an enveloped virus of the orthomyxoviridae family.

The genome of the type A virus is separated into 8 independently assorted RNA
segments, which allows for production of hybrid genotypes during multi-virus
infections. Influenza A virus has the unique capacity to undergo genetic variation
by mutating its major surface protein, hemagglutinin (HA), without changing the
function of the HA. These genetic changes, typically associated with HA, render
current influenza vaccines ineffective against strains different from the vaccine
strain and call for the periodic production of completely new vaccines to
overcome antigenic drift or shift (Cox & Subbarao, 2000).
Swine influenza virus (SIV) causes an acute respiratory disease in
pigs. The pathogen is an important component of the porcine respiratory disease
complex and by itself can have a significant impact in the swine industry
(Easterday, 1980; Rajao et al., 2018). A typical outbreak of respiratory disease
caused by SIV is characterized by sudden onset, and rapid spread within a herd
(Vincent et al., 2008). Clinical symptoms associated with SIV may include
coughing, sneezing, nasal discharge, elevated rectal temperature, lethargy,
breathing difficulty, and depressed appetite (Easterday, 1980; Vincent et al.,
2008).

Some studies have suggested that SIV infections can lead to

reproductive disorders such as abortions (Vincent et al., 2008). While morbidity
rates may reach 100% with SIV infections, mortality rates are generally low
(Easterday, 1980; Vincent et al., 2008). SIV in pigs can be transmitted to
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humans, which has raised concerns that such viruses could contribute to the
generation of pandemic influenza. Such concerns are indeed demonstrated in
2009 pandemic influenza triggered by a swine-originated H1N1 virus as well as
in recent transmission into human populations by a variant swine H3N2 virus
(Maines et al., 2009; Wong et al., 2013).
Two subtypes, H1N1 or its variant H1N2 and H3N2, are a major cause of
worldwide swine influenza (Vincent et al., 2008). There are several antigenic
clusters or clades within each subtype (Hause et al., 2010; Hause et al., 2012;
Rajao et al., 2018).

Any subtle changes in the receptor binding site or

neutralization-sensitive region through evolving viral evolution for replication
fitness have a negative influence on the effectiveness of a vaccine, which is
formulated for a particular strain. Additional mutations in N-linked glycosylation of
HA can promote viral evasion of antibody recognition by altering the
oligosaccharide layer surrounding HA. Glycan residues can restrict the binding of
some antibodies to their epitopes, leading to loss of antibody recognition and
immunogenicity in a phenomenon known as glycan shielding (Wanzeck et al.,
2011). Additionally, mutation and genetic drift occur preferentially at positions in
the HA globular head that are not protected by glycans (Das et al., 2010). Glycan
residues also influence receptor binding and consequently can affect viral
replication kinetics. Our recent work showed that the relocation of the
hemagglutinin N-linked glycosylation site from N142 to N144 renders swine
influenza virus δ-cluster viruses resistant to preexisting antibody-mediated
neutralization (Hause et al., 2012).
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Hemagglutinin (HA), the major influenza virus surface protein, is a
homotrimer, with each monomer consisting of an outer HA1 subunit that is linked
covalently to a membrane-anchoring HA2 subunit (Wiley & Skehel, 1987). HA1
binds the virus to its cellular receptors, which are sialic acid residues of
glycoproteins or glycolipids, and following endocytosis, HA2 mediates the fusion
of viral and cellular membranes in a pH-dependent manner to permit entry of the
genome complex into the cell (Bullough et al., 1994a).
HA2 constitutes the core machinery that drives virus-cell or cell-cell fusion
leading to influenza virus entry (Bullough et al., 1994a; Wiley & Skehel, 1987).
The N-terminal 20 residue of HA2 protein is a fusion peptide (F) that is the most
highly conserved region in HA2. In addition to the fusion peptide, HA2 consists of
5 helixes (A, C, D, G, H), 2 β–strands (E and F), and 1 loop (B) (Figure 9). After
being subjected to a low pH, the fusion peptide gets exposed and inserted into
the membrane, followed by a cascade of structural rearrangements of HA2.
These structural rearrangements transform HA2 to post-fusion state (fusogenic
structure) from a pre-fusion state (pre-fusogenic structure) that accompanies the
completion of virus-cell fusion event (Figure 9). It has been established that viruscell fusion process is largely driven by a trimeric coiled-coil formed by the long
and central CD helix (residues 75 to 126) in combination with the A helix
(residues 38 to 58) that packs against the central helical bundle (Bullough et al.,
1994a; Wiley & Skehel, 1987). This structure can be designated as HA2 fusionactive (Ekiert et al., 2009).

58

Figure 9. Crystal structure of the influenza virus HA protein and structural
characterization of its rearrangement.
(a) Overview of a trimeric HA0 precursor, shown as a ribbon diagram. One monomer is
colored in yellow (HA1 subunit) and red (HA2 subunit) illustrating the locations of
subdomains. The two other monomers that make up the trimer are shown in blue and
green. (b) Ribbon diagram of a monomeric, cleaved form of the HA. Featured subdomains
are highlighted with different colors: helix A (green), loop B (orange), helix C (pink), helix
CD (blue), helix D (purple), β-sheet EF (cyan), helix G (black) and fusion peptide (red).
Modified from Thomas Han and Wayne A. Marasco, Ann N Y Acad Sci. 2011 January;
1217: 178–190.

There are several interesting conformational changes associated with the
formation of a post-fusion HA2 structure following low pH triggering (Bullough et
al., 1994a; Bullough et al., 1994b; Wiley & Skehel, 1987). One of these changes
is in the B loop connecting A and CD helices (residues 55 to 76) that are in a
loop conformation in the native HA2 structure, but become helical during the
HA2-mediated fusion process. Conversely, residues 106-111, a portion of central
CD helix, change from helix to a loop structure during the HA2-mediated fusion.
Another interesting change is that the H helix becomes a disordered structure
following low pH triggering. Such conformational changes are normally transient
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during the fusion process and also probably occur in a sequential manner.
Each of these changes associated with HA2 might be collectively called fusion
intermediates.
Structure and function of these fusion intermediates are likely conserved
among different influenza A viruses because they are critical to virus entry. It can
be envisioned that any spatial and temporal disruption, even subtle, in the
formation of these fusion-active intermediates will block conversion of HA2 to the
post-fusion conformation and virus fusion and subsequently inhibit virus
replication. Earlier studies of the mechanism of influenza virus neutralization
have demonstrated that antibodies targeting the fusion more likely exhibit an
overall cross-reactive tendency in neutralizing different subtypes whereas
antibodies targeting receptor binding are strain-specific (Bright et al., 2008; Bright
et al., 2007; Perrone et al., 2009). This phenomenon has recently been
confirmed and extended in several independent studies (Bommakanti et al.,
2010; Ekiert et al., 2009; Kashyap et al., 2008; Kashyap et al., 2010; Sui et al.,
2009; Wang et al., 2010b; Wang et al., 2010c).
By using similar techniques such as phage display selection on
recombinant HA antigen either for human influenza virus-specific antibodies or a
human antibody library, investigators found a handful of antibodies represented
by CR6261 and F10 that can effectively neutralize multiple subtypes, including
H1, H2, H5, H6, H8, and H9, and protect mice from lethal challenge with HIN1
and H5N1 viruses (Ekiert et al., 2009; Kashyap et al., 2008; Kashyap et al., 2010;
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Sui et al., 2009). Several lines of evidence demonstrated that these antibodies
target viral fusion machinery largely constituted of HA2, rather than the receptorbinding site in HA1 (Ekiert et al., 2009; Kashyap et al., 2008; Kashyap et al.,
2010; Sui et al., 2009). It has been shown that CR6261 and F10 bind to different
conformational epitopes present in the shorter A helical region (residues 38 to
58) probably in the context of the adjoining region and prevent low pH-triggered
fusion, thereby neutralizing influenza viruses (Ekiert et al., 2009; Sui et al., 2009).
In addition to F10 and CR6261, new broad-spectrum protective antibody, 12D1,
which binds to a liner epitope (70-106 amino acid residues) present in the HA2
long CD helix, has been recently described (Wang et al., 2010b). The A helix
consisting of 21 residues (a target of CR6261 and F10) and the CD helix
consisting of 52 residues (a target of 12D1) are very similar among various
subtypes of influenza viruses in terms of primary sequence and structure. Thus
these conserved HA2 structures represent an important target for universal
vaccine discovery and development against influenza viruses.
Despite the significant progress recently made in discovering broadly
reactive antibodies against divergent influenza viruses, it is not entirely clear why
CR6261, F10, and 12D1 have been so difficult to identify (Ekiert et al., 2009; Sui
et al., 2009; Wang et al., 2010b). While very low levels of serum antibody specific
to 12D1 epitope were detected in human subjects (Wang et al., 2010b), overall
these antibodies are not frequently induced, either by immunization with
influenza vaccines or through natural infection. A possible explanation is that the
neutralizing epitopes present in fusion intermediates of HA2 are transient in
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nature, existing for a limited period of time - post low pH triggering, but
disappear after the completion of HA2 conformational changes. Such a short
time frame may significantly reduce the chance for fusion intermediates to
present their epitopes to the immune system. Alternatively, HA1 may restrict the
exposure of epitopes associated with HA2, thereby resulting in a limited immune
response. It is likely that these scientific challenges should be taken into account
when rational design of a universal influenza vaccine is performed.
Significantly, vaccination with a linear peptide mimicking the CD helix
provides protection against a subset of distinct viral subtypes in a murine
influenza model (Wang et al., 2010b). In line with the recent progress toward a
universal influenza vaccine, a recent study showed that vaccination of mice with
modified HA2 protein expressed in Escherichi coli protects mice from pathogenic
influenza challenge (Bommakanti et al., 2010). These elegant studies provided
proof-of-concept for the feasibility of a HA2-based universal approach in
stimulation of broad-spectrum immunity, which supports our study here.
Considering that a stretch of residues within the A helix is similar among different
subtypes and also reacts with high affinity to CR6161 or F10, it is possible that a
linear peptide mimicking the A helix can be tested for induction of a CR6261- or
F10-like neutralizing antibody. However, an epitope that CR6261 or F10
recognizes is in a conformational state and some of its residues are not
particularly exposed in native viruses (Ekiert et al., 2009; Sui et al., 2009). The
cryptic nature of these B-cell epitopes may challenge the linear peptide-based
approach as one used for generation of 12D1-like antibody responses (Wang et
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al., 2010b), indicating innovative strategies may be required to present the
epitope in a native context. Furthermore, despite broad-spectrum activity,
antibodies derived from the CD peptide immunization seem more efficacious in
protecting against homologous than heterologous groups of influenza A viruses
(Wang et al., 2010b), suggesting that further optimization of antigen presentation
might be needed to make a vaccine candidate equivalently protective against all
subtypes.
In this study we proposed to explore swine influenza virus’s fusion
machinery as targets for universal swine influenza vaccine development. We
initially focused on the detailed characterization of SIV variants with mutations on
the A-helix and CD-helix of HA2 stem region and then selected a vaccine
candidate from HA2 mutants for evaluation of its protective efficacy against SIV
H1N1 and H3N2 subtypes in pigs.

4.2

Materials and Methods

4.2.1 Cell and viruses.
Swine testicle (ST), Madin-Darby Canine Kidney (MDCK), and 293T human
embryonic kidney cells were purchased from ATCC. These cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) containing 10 % FBS at 37 °C with
5 % CO2. Primary epithelial cells from porcine trachea were developed from a
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healthy 3-week old piglet. For viral propagation, fetal bovine serum was
omitted from the DMEM.
4.2.2 Influenza reverses genetics system and HA2 mutagenesis
H1N1 A/WSN/33 reverse genetics system (RGS) was kindly provided by
E. Hoffmann, St Jude Children’s Research Hospital (Hoffmann et al., 2000). This
system contains eight plasmids: pHW181-PB2, pHW182-PB1, pHW183-PA,
pHW184-HA, pHW185-NP, pHW186-NA, pHW187-M, and pHW188-NS. The fulllength HA gene from H1N1 A/swine/North Carolina/3793/08 (Hause et al., 2012)
was amplified and cloned into pHW2000 vector that derived H1N1 A/WSN/33
RGS.

A

combined

RGS

that

contains

seven

segments

(PB1/PB2/PA/NP/NA/M/NS) from WSN/33 system and one HA segment from
A/swine/North Carolina/3793/08 was used as the template to create single-point
substitutions targeting the A and CD helical region of the HA2. We also included
mutations targeting the B-loop in our mutagenesis. The standard site-direct
mutagenesis was performed on the HA plasmid using a QuickChange II sitedirected mutagenesis kit (Agilent technologies).
4.2.3 Production of infectious IAVs by reverse genetics.
Recombinant A/WSN/33 displaying SIV HA and its derivatives were
produced by the standard reverse genetic technique. Briefly, to rescue the
viruses, 293T and MDCK cells were co-cultured at approximately 70 %
confluence in 12-well plates and transfected with a mixture of eight plasmids,
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which were prepared in Trans-LT1 (Mirus) and Opti-MEM I medium according
to the manufacturer’s instructions. The mixtures were incubated at room
temperature for 45 min before they were added to the cells. After 6 h culture,
transfection mixtures were replaced with Opti-MEM I medium followed by an
additional 18 h incubation at 37 °C. Then, Opti-MEM I medium containing
tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-trypsin (Sigma-Aldrich) at
a concentration of 1 µg per was added to each well. At 72 h post-transfection,
viral supernatants were collected, centrifuged at 2000 r.p.m. (Sorvall Legend
Mach 1.6R, rotor 75003348) for 10 min, which were followed by storage at −80°C
until further analysis. The resulting viruses were confirmed for introduced
mutations through RT-PCR coupled with traditional Sanger sequencing
approach.
4.2.4 Effects of mutations on the HA binding to erythrocytes.
We used this traditional assay to determine whether the introduced
mutations disrupt the ability of HA to bind to red blood cells, an indicator of
receptor binding. Wild type and mutants generated with the above procedure
were diluted in a volume of 50 μl in PBS in 96-well round-bottom microtiter plates
(Corning-Costar, Cambridge, Mass.). Chicken erythrocytes were washed twice
with PBS and re-suspended at a concentration of 2% (vol/vol). Erythrocytes (50
μl) were added to the viruses, and plates were incubated at RT for 2 hrs. The
highest dilution of the viruses that caused complete hemagglutination was
considered the HA titration end point.
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4.2.5 Effects of mutations on HA protein synthesis and cell surface
expression (trafficking).
293T cells were transiently transfected with mutant HA clones in parallel
with the wild type HA in 6-well culture plates using the Trans-LT1 (Mirus). At 72 h
post-transfection, cells were fixed with 2% (wt/vol) paraformaldehyde (Electron
Microscopy Sciences, Hatfield, PA) followed by permeabilization with 0.2%
(vol/vol) Triton X-100. Cells were further incubated with a human anti-HA
monoclonal antibody and goat anti-human secondary antibody conjugated to
FITC, and was then washed briefly in PBS before quantitative analysis by flow
cytometer. Similar measurement to determine the level of HA protein expression
on the cell surface was conducted for transfected cells without membrane
perturbation.
4.2.6 Effects of mutations on viral replication.
MDCK and ST and porcine primary tracheal cells were infected in parallel
with either the WT or the mutants at various multiplicity of infection (MOI).
Aliquots of the tissue culture supernatant were taken at periodic intervals for
determining viral replication kinetics. Virus replication experiments were
conducted three times, each performed in triplicate.
4.2.7 Animal experimental subjects, clinical evaluation, and sample collection.
All swine influenza antibody-negative 6-week old pigs were acquired from
Midwest research farm located in Minnesota. Upon arrival, these pigs were kept
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for one week in isolation rooms at Animal research facility, South Dakota State
University. The project were reviewed and approved by the institution’s Animal
Care and Use Committee (IACUC) prior to its being conducted.

Euthanasia

procedures were compliant with the recommendations of the most recent
American Veterinary Medical Association (AVMA) Panel on Euthanasia.
All piglets were monitored daily for evidence of respiratory disease
including rectal temperature. Samples of sera and nasal swabs were prepared
from each pig prior to vaccination. Serum samples were stored at -20°C until
they were tested for antibody reactivity in a hemagglutination inhibition (HI) assay
and an enzyme-linked immunosorbent assay (ELISA), respectively. Samples of
nasal washes were stored at -80°C until being used to carry our genetic analysis
of viral RNA by RT-PCR and virus isolation in MDCK, respectively.
4.2.8 Experimental immunization and virus challenge procedure.
Two vaccine candidates were used in this study. Wild type H1N1 WSN/33
was used as a control. N439G virus was derived from WSN33 with a porcine HA
with single-point substitution at HA position 439. The N439G was replicative in
cell cultures but attenuated. Vaccination/challenge group contained 8 pigs for
each vaccine candidate, while control (receiving no vaccine and no challenge)
and challenge (receiving no vaccine but virus challenge) groups had 4 and 8
pigs, respectively. For challenge, pandemic H1N1 A/Swine/Minnesota/09 and
A/Swine/Minnesota/2073/2008 were used. Each vaccine or challenge control
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group was equally split into two sub-groups (4 animals each sub-group) and
each sub-group received H1N1 and H3N2 challenge, respectively, as described
below.
The first vaccination was conducted by intranasally delivering 104 TCID50
WSN/33 and 104 attenuated N439G influenza viruses into pigs in vaccination
groups. The vaccines were sprayed, ½ in each naris, through an insulin syringe
fitted with a 29 gauge needle.

Piglets were held head vertical, but not

tranquilized for the procedure. Two weeks later, the second vaccination was
conducted similarly including same immunization route and dose. For control
groups, PBS was used for intranasal inoculation into pigs. Two weeks later after
the second vaccination, 8 vaccinated animals (with WT WSN/33 or N439G) were
split into two sub-groups (four animals per sub-group) and the pigs in the two
groups were then challenged intranasally, respectively, with 1 x 106 TCID50
infectious

does

of

H1N1

A/Swine/Minnesota/09

and

A/Swine/Minnesota/2073/2008. 8 animals receiving PBS inoculation were also
split into two-subgroups (four animals each) and each sub-group was challenged
with two subtypes of swine influenza, respectively.
The pigs were monitored daily for clinical symptoms. Half of the pigs (2) in
each group were euthanized at 3DPC and the remaining animals were
euthanized at 5DPC. Serum and clinical samples were collected and assessed
for immune responses and evidence of viral infection in the lungs.

Lung
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homogenates were collected at 3DPC and 5DPC and prepared for viral
isolation through cultivation in MDCK cells.
4.2.9 Serological assays.
The hemagglutination inhibition (HI) assay was conducted by following the
WHO standard procedure. Briefly, 100 μl serum was mixed with 300 μl of
receptor-destroying enzyme (RDE) (Denka Seiken Co., Ltd., Japan) and
incubated overnight in a 37°C water bath. The mixture was heated in a 56°C
water bath for 30 min to inactivate the remaining activity of RDE. After cooling to
room temperature, 100 μl physiological saline (0.85% NaCl) was added to serum
so that the final dilution of serum stock was 1:5. To remove nonspecific
agglutinins, 25 μl of 5% packed chicken red blood cells (RBCs) (Lampire
Biological Laboratories, Pipersville, PA) was added to 500 μl RDE-treated and
heat-inactivated sera. After an additional incubation at 4°C for 1 h, the mixture
was centrifuged at 1,200 rpm for 10 min; the supernatant was collected,
aliquoted, and frozen at −20°C or directly used in the following assays.
Reference antigens were titrated by 2-fold serial dilutions with 50 μl
physiological saline and then incubated with 50 μl of 0.5% RBCs. Standardized
antigens of 4 hemagglutination units per 25 μl were prepared based on the
titration. Pig serum samples and reference sera were diluted serially 2-fold from
1:5 with 25 μl physiological saline and incubated with 25 μl standardized antigens
at room temperature for 15 min, followed by the addition of 50 μl of 0.5% RBCs
before incubating for an additional 30 min. Physiological saline and serum
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controls, as well as antigen back titration, also were performed for validation. A
titer of 40 was used as a threshold, i.e., a sample with a titer of less than 40 was
judged as negative, and those with a titer equal to or higher than 40 were viewed
as positive.
The microneutralization (MN) assay was performed on MDCK cells as
described in the WHO standard manual. Prior to neutralization, a 50% tissue
culture infectious dose (TCID50) of reference viruses was determined on MDCK
cells, and then the viruses were diluted to 200 TCID50/100 μl with DMEM
containing 2 μg/ml of TPCK-trypsin, 0.3% BSA, and antibiotics. RDE-treated and
heat-inactivated pig serum samples and reference ferret antisera were 2-fold
serially diluted with DMEM containing 2 μg/ml of TPCK-trypsin, 0.3% BSA, and
antibiotics and mixed with 100 μl TCID50 of the reference viruses to react for 1 h
at 37°C. The mixture was transferred into 96-well plates that contained 100 μl
MDCK cell suspension (1.5 × 104 cells/well). The plate was incubated overnight
at 37°C with 5% CO2. Negative and positive serum controls, virus controls, cell
controls, and virus back titration also were performed to validate procedures and
results. The cells were fixed with 100 μl of 80% cold acetone at room
temperature for 10 min and used for ELISA. Briefly, cells were incubated with the
primary antibody, anti-influenza B virus nucleoprotein antibody (Abcam,
Cambridge, MA), and then with the secondary antibody, goat anti-mouse IgGhorseradish peroxidase (HRP) (Sigma-Aldrich, St. Louis, MO), before being
washed. The substrate ortho-phenylenediamine (OPD) and stop solution then
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was added. The absorbance (optical density at 490 nm [OD490]) was read and
recorded for further analysis.

4.3

Results

4.3.1 Rationale.
Our approach was to identify and characterize “stabilized” HA fusion
intermediates that may present the HA2 subunit to the immune system as it
exists post low pH triggering but prior to fusogenic structure formation (e.g.,
locked nonfusogenic strategy) (Bullough et al., 1994a; Bullough et al., 1994b;
Wiley & Skehel, 1987). Through the introduction of appropriate mutations into the
A-helix and CD-helix, we can render A-helix and CD helix fully accessible to
immune system. As a result, some HA intermediate candidates can be identified
and the selected candidate will be tested in a pig pilot study to evaluate
protection efficacy against infection by swine influenza H1N1 and H3N2
subtypes.
4.3.2 Production of HA constructs with mutations in the A and CD helical region
and B loop.
We generated two groups of mutations targeting the large portion of the
CD helix in the context of swine HA reverse genetics segment by site-directed
mutagenesis (Figures 10 and 11).
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Figure 10. Amino acid sequence of portion of HA2 protein (residues 40 to
129) and substitution mutants generated in this study.
A portion of the CD helix consists of an unbroken 3-4 heptad repeats extending from
residues 77 to 90, a spacer surrounding the residue isoleucine at position 91, and another
the 3-4 heptad repeat. Please note that positions of amino acids here refer to the
numbering of HA2 subunit.
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Figure 11. Mutations in CD helix positions in the context of CD helix
structure.

The first group consisted of mutations at the helical a/d positions that
involved substitution of highly conserved residues with known helix breakers as
such Glycine, resulting in the abrogation of the secondary structure of the trimeric
coiled-coil. Individual mutations in the first group were I421G, L424G, V428G,
G431A, I435G, N439G, and L442G (numbering is based on the full-length HA
protein sequence of SIV H1N1 beginning from the N-termini). The second group
involved mutations at the e/g positions that will likely disrupt the packing
interaction between the coiled-coil structure and the A helix. Individual mutations
in the second group are N425G, K427G, F432G, D434G, W436G, Y438G,
L443G, and L445G. To ensure that we had a sizable pool of HA2 fusion
intermediates with desired protein stability and structural integrity for selection
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toward further evaluation of the vaccine efficacy in pigs, we generated an
additional panel of mutations targeting the B-segment of HA2 in a way that both
A helix and CD helix (containing a unique set of neutralizing determinants) are
not disrupted. Three mutations, K402P, A409P, and K412P targeting the B-loop
were produced. In summary, total 18 mutants were generated in SIV H1 RGS
segment, which were confirmed by PCR coupled with traditional Sanger
sequencing method.
4.3.3 Effects of single-point HA2 substations on viral infectivity.
Co-transfection of 293T/MDCK cells was performed as described in the
Material and Method section under the identical conditions for WT and all mutant
RGS plasmids. Harvested supernatants at 72 h post-transfection were passaged
in MDCK one time and the resultant supernatants were measured for HA activity
as an indication of the mutation-induced effect on viral infectivity. As summarized
in Table 5, 7 mutants were successfully rescued and replication-competent, while
majority of mutants (11 total) were replication-incompetent. Further analysis
showed that viruses with A409P substitution in the B-loop or D434G substitution
in the CD helix displayed a WT-like infectivity, indicating that these two mutations
had no effects on viral infectivity. Furthermore, one virus with L445G mutation
exhibited a slightly reduced infectivity. Interestingly, four viruses (G431A, I435G,
N439G, and N425G), all in the CD helix, were significantly attenuated (i.e., 50%
reduction in HA titer when compared to WT virus). Among them, the virus with
N439G mutation was most affected with only 25% of WT infectivity observed.
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Table 5. Effects of HA2 mutations on viral infectivity.
Viruses

Location

Position Titers

WT (1+7)

Effects

++++

K402P

B loop

-

Loop-helix transition

A409P

B Loop

++++

Loop-helix transition

K412P

B Loop

-

Loop-helix transition

I421G

CD helix

a

-

Triple CD helix formation

L424G

CD helix

d

-

Triple CD helix formation

V428G

CD helix

a

-

Triple CD helix formation

G431A

CD helix

d

++

Triple CD helix formation

I435G

CD helix

d

++

Triple CD helix formation

N439G

CD helix

a

+

Triple CD helix formation

L442G

CD helix

d

-

Triple CD helix formation

N425G

CD helix

e

++

CD-A helix interaction

K427G

CD helix

g

-

CD-A helix interaction

F432G

CD helix

e

-

CD-A helix interaction

D434G

CD helix

g

++++

CD-A helix interaction

W436G

CD helix

e

-

CD-A helix interaction

Y438G

CD helix

g

-

CD-A helix interaction

L443G

CD helix

e

-

CD-A helix interaction

L445G

CD helix

g

+++

CD-A helix interaction

Note: 1. Summary data from three independent experiments with titers measured in HA
assay. Viruses were passaged one time in MDCK after 293T/MDCK co-cultures involving
transfection.
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2.
"++++" means 6-8 log2 of HA units; "+++" 5-6 log2 of HA units; "++" 2-4 log2 of
HA units; "+" less than 1 log2 of HA units; and "-" with no detectable HA units.

4.3.4 Effects of mutations on viral replication kinetics.
Replication kinetics data in MDCK (Figure 12) and ST (Figure 13)
discriminated viruses into three groups based on their growth curves as a
function of time following infection.

First group consisted of WT and L445G

mutant, which replicated at a level higher than rest of mutant viruses. L445G
mutation seemed to make the virus gain replication fitness in these two cell lines
because the mutant replicated slightly better than the WT virus. Second group
that only contained G431A mutant replicated at an intermediate level between
WT and attenuated groups. The G431A mutant was attenuated approximately by
1.0 to 2.0 log when compared to WT group but was more robust in the replication
than the attenuated group by 1.0 log in the average. Third group contained
D434G, I435G, N439G, A409P, and N425G, which were highly attenuated by 2-4
log when compared to the WT virus and L445G mutant.
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Figure 12. Effects of mutations on viral replications in MDCK cells.
Replication kinetics of the WT and HA2 mutant viruses in infected MDCK cells.
MDCK cells were infected with either the parental WT or the indicated mutant
virus stock at an MOI of 0.1. Virus production following infection of MDCK cells
was monitored at various times postinfection by measuring viral activity (TCID50
per ml) in the culture supernatant. The data presented in this figure are
representative of at least three independent infections.
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Figure 13. Effects of mutations on viral replication kinetics in ST cells.
Replication kinetics of the WT and HA2 mutant viruses in infected ST cells. ST
cells were infected with either the parental WT or the indicated mutant virus stock
at an MOI of 0.1. Virus production following infection of ST cells was monitored at
various times postinfection by measuring viral activity (TCID50 per ml) in the
culture supernatant. The data presented in this figure are representative of at
least three independent infections.
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To determine the effects of these HA2 mutation on viral replication in
porcine primary tracheal epithelial cells (Figure 14), the predominant in vivo
target cell for swine influenza, we next compared the replication kinetics of WT
and HA2 mutant virus stocks in cultures of porcine primary tracheal cells. Virus
stocks from WT and mutant viruses were prepared with MDCK cells by
harvesting medium at 3 days post infection. The titers of the various virus stocks
were determined for infectivity by using the standard TCID50 assay for MDCK
cells, and primary lung cells were infected in parallel with either the wild type or
the HA mutants at a multiplicity of infection (MOI) of 0.1 and assayed for virus
replication as described above. The data in Figure 14 demonstrated that
the L445G mutant replicated similarly as the WT virus in infected MDM cells.
Interestingly, G441A mutant, an intermediate phenotype between the WT and
significantly attenuated group, was substantially attenuated in primary cells.
Furthermore, D434G mutant replicated only transiently in primary lung cells. The
other four mutants (I435G, N439G, A409P, and N425G) replicating modestly in
MDCK and ST cells failed to replicate in primary cells. These data indicate that
the some HA2 residues are in fact an important determinant of viral replication in
natural target cells such as lung epithelial cells, despite the evident lack of their
influence on viral replication levels in transformed cell lines. Thus, these
observations suggest in vivo functions of HA2 critical residues in the B-loop and
CD helix that are not adequately reflected in simple infections of cultured cell
lines.
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Figure 14. Effects of HA2 mutations on viral replication kinetics in primary
porcine tracheal epithelial cells.
Replication kinetics of the WT and HA2 mutant viruses in primary porcine
tracheal epithelial cells. Primary cells were infected with either the parental WT or
the indicated mutant virus stock at an MOI of 1.0. Virus production following
infection of primary cells was monitored at various times postinfection by
measuring viral activity (TCID50 per ml) in the culture supernatant. The data
presented in this figure are representative of at least three independent
infections.
We also determined whether these mutations affected HA protein
expression by using flow cytometer analysis. As demonstrated in Figure 15, most
of introduced mutations exhibited little or no effects on HA protein expression.
Only four mutations showed some minor to moderate effects on HA protein
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expression, including V428G, D434G, Y438G, and L424G. It seems that there
is no correlation between HA expression level and viral infectivity. For example,
D434G affecting HA expression by approximately 20% has resulted in WT-like
replication phenotype. On the other hands, K402P, K427G, F432G, and W436G
mutants with a WT-like HA expression level all failed to replication in ST and
MDCK cell lines.

Figure 15. Effects of HA2 mutations on HA protein expression measured by
FACS analysis.
293T cells were transfected with equal amounts of the parental WT or single
residue point-substitution mutant DNA. After 48 h, HA expression was analyzed
with HA-specific antibody through FACS. The level of HA protein expression by
WT HA was set at 100%. HA expression for each mutant was normalized by
comparison with WT. These data represent an average of at least four
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independent experiments. Experimental variability indicated by standard
deviation bars.
4.3.5 Attenuated N439G mutant protects pigs from infection by both
homologous and heterologous virus challenges.
We selected N439G mutant as our vaccine candidate based on the
following three reasons. First, N439G significantly affected influenza virus
replication as measured in both ST and MDCK cell lines. Second, this mutation
rendered virus replication goes undetectable in primary porcine tracheal epithelial
cells.

Third, this mutation may disrupt the formation of triple CD helix but

maintain the structural integrity of the A helix and B-loop so antibodies against
these conserved regions can be produced.
Animal experiment for evaluation of N439G-mediated protection efficacy in
pigs was schematically presented in Figure 16. Two weeks following second
vaccination, four vaccinates were challenged intranasally with 1 x 106 TCID50 of
H1N1 A/Swine/Minnesota/09, while the other four vaccinates were intranasally
challenged with 1 x 106 TCID50 of H3N2 A/Swine/Minnesota/2073/2008. Nasal
swab samples were collected at 3 DPC for virus isolation on MDCK cells. Also
two animals from each group were euthanized and lung samples collected for
virus isolation. At 5 DPC, all animals were euthanized and nasal and lung
samples were collected for virus isolation.
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Figure 16. Pig study evaluating protection efficacy of N439G virus against
infections of H1N1 and H3N2 swine influenza viruses.

Pigs challenged with SIV H1N1 or H3N2 did not exhibit obvious clinical
symptoms including respiratory distress and nasal or ocular discharge. No
significant differences between vaccinates and controls was observed with
regard to rectal temperature and body weight (date not shown). At 5 DPC, piglets
were euthanized and necropsies were performed. All animals including controls
(receiving no vaccination) exhibited none of clinical lung lesions. The lack of
detectable lung lesions in both vaccinated and non-vaccinated animals
demonstrates that 11 week-age of these pigs may not be susceptible to SIV
infection and development of clinical responses.
We next determined whether vaccinated animals were protected from
infection by challenging with viruses. At 3 DPC, viruses were isolated from nasal
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washes from all challenged animals. The average 1-log decreases in viral
load, however, were observed in both N439G and WSN/33 vaccination group
when challenged with H3N2 (Figure 17). In contrast, no evident reduction in viral
titers was observed in H1N1 challenge group. Remarkably, a significant
reduction in viral load was observed at 5 DPC from nasal washes in vaccination
groups (Figure 18). For example, in N439G group, only residual amount of H3N2
replication was detected, while more than 2.5 log reduction in viral load observed
in H1N1 challenged animals. In WSN/33 vaccination group, little amount of H1N1
replication was found, while more than 2.5 log reduction in viral load observed in
H3N2 challenged animals. Neither control nor vaccinated animals showed
detectable viral replication in lungs at both 3 DPC and 5 DPC. Again this may
reflect that pigs at age of 11 week may not be highly susceptible to SIV infection.
In summary, by viral load analysis, N439G and WSN/33 vaccination substantially
protected vaccinated pigs from infections of both H1N1 and H3N2.
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Figure 17. Viral loads present in nasal swabs of pigs at 3-day post infection
(DPI).
The nasal washes were collected from pigs as 3DPC by instilling 2 ml of PBS
using a sterile 25-to-28-gauge cannula into the nostrils and collecting the washes
by draining to sterile containers or petri dishes. Nasal washes collected in the
petri dishes were transferred to 1.5-ml tubes and then centrifuged at 500 × g for 6
min at 4°C to remove any debris. Serial 10-fold dilutions of the sample were
inoculated on MDCK cell culture plates after the plates were washed with sterile
PBS. The inoculated cell culture plates were incubated for 5 days at 37°C. After 5
days, the infected cell culture plates were washed with PBS, fixed in 80%
acetone, and allowed to dry. The plates were stained for determinations of virus
titers in nasal washes by indirect immunofluorescence assay. Virus titration was
determined using the Reed and Muench formula to find the 50% endpoints
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Figure 18. Viral loads present in nasal swabs of pigs at 5-day post infection
(DPI).
The nasal washes were collected from pigs as 5DPC by instilling 2 ml of PBS
using a sterile 25-to-28-gauge cannula into the nostrils and collecting the washes
by draining to sterile containers or petri dishes. Nasal washes collected in the
petri dishes were transferred to 1.5-ml tubes and then centrifuged at 500 × g for 6
min at 4°C to remove any debris. Serial 10-fold dilutions of the sample were
inoculated on MDCK cell culture plates after the plates were washed with sterile
PBS. The inoculated cell culture plates were incubated for 5 days at 37°C. After 5
days, the infected cell culture plates were washed with PBS, fixed in 80%
acetone, and allowed to dry. The plates were stained for determinations of virus
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titers in nasal washes by indirect immunofluorescence assay. Virus titration
was determined using the Reed and Muench formula to find the 50% endpoints
We next used the standard serological assay to examine virus-specific
antibody responses in vaccinated animals. HI antibody response was determined
in serum samples collected from animals prior to vaccination and on the day of
challenge.

Figure 19. High-titer HI antibodies were elicited in N439G vaccinated pigs.
Characterization of challenge H1N1 virus-specific HI antibody at the day of
challenge in pigs vaccinated with WT H1N1 WSN/33 and N439G viruses. The HI
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antibody titer is expressed as the reciprocal of the highest serum dilution
showing complete inhibition of agglutination using 4 HAU units/25 µL. Horizontal
bars show the means antibody titers for group with the range indicated by
standard error bars. The data presented in this figure are representative of three
independent experiments, each assayed in duplicate.
With 1:40 as a cut-off value, none of unvaccinated PBS or WSN/33
vaccinated pigs demonstrated detectable anti-H1N1 HI titers (Figure 19). All
N439G vaccinated animals (had detectable serum HI antibody titers against
H1N1 antigen. We did not observe a clear correlation between the presence of
HI antibody titer and protection from infection, as some WSN/33 vaccinated pigs
that were protected from virus infection following challenge were negative in HI
antibody response (i.e., titers of less than 1:40).
Together, the above observations indicate that piglets responded well to
intranasal vaccination with both N439G and WSN/33 viruses, thereby limiting
infection via the nasal route by both homologous and heterologous SIV
challenge. These results strongly suggest that the vaccination described in this
work restricts influenza infection in pigs, and suggests that it may have the
potential to limit the dissemination of the virus among pigs in a vaccinated herd.
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4.4

Discussion
We report here that HA protein of swine influenza virus can tolerate some

mutations in the B-loop and CD helix without substantially compromising its
function. These mutations, however, have significantly attenuated influenza virus
replication in both cell lines and porcine primary tracheal epithelial cells. Results
of our HA mutagenesis experiments reveal several interesting findings. First,
three mutations (G431A, I435G, and N439G) theoretically designed to disrupt the
formation of triple helix formation (Bullough et al., 1994a; Bullough et al., 1994b;
Wiley & Skehel, 1987) do not completely abrogate the replication competency of
mutant viruses. Second, three mutations (N425G, D434G, and L445G) designed
to inhibit an interaction between helix A and helix CD (Bullough et al., 1994a;
Bullough et al., 1994b; Wiley & Skehel, 1987) do not also render mutant viruses
replication-incompetent. Third, the virus survives A409P mutation that affects a
transition from B-loop to B-helix following low pH triggering (Bullough et al.,
1994a; Bullough et al., 1994b; Wiley & Skehel, 1987). These new observations
should offer new functional insights into future function-structure study of swine
influenza HA protein.
Comparative study of viral replication kinetics between transformed cell
lines and primary tracheal epithelial cells reveal some interesting differences for
these mutant viruses. N425G, I435G, N439G, and A409P mutants that replicate
in MDCK and ST are incapable of replicating in primary cells. It has been thought
that MDCK and ST are not effective innate immunity-expressing cell lines (Hause
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et al., 2012; Seitz et al., 2010). The failure of mutant viruses replicating in
primary cells, not in MDCK and ST cell lines, may suggest that HA protein of
swine influenza A virus may have a novel anti-host function, which is separable
from its conserved entry and fusion function.

Several previous studies have

indeed presented good evidence that HA protein has an important role in
influenza pathogenesis as well as in communication with host proteins (BottcherFriebertshauser et al., 2014; Cline et al., 2013). Further investigation of these
HA mutants may continue to support this emerging theme regarding a role of HA
in viral pathogenesis.
Among 18 single-point mutants, only 7 mutants showed various levels of
replication whereas other 11 mutants are completely replication-incompetent.
Also attenuation for 7 mutants can be caused by several potential reasons. For
example, these mutations may block virus-cell fusion and as a result inactivate
viral infectivity. It is possible that mutations may affect functional HA trimer
formation or stability, which in turn block viral entry to cells. On the other hand,
there is a possibility that these mutations may affect HA’s interactions with other
viral proteins such as NA or M2 or M1. Mechanistic studies towards addressing
these defects should be pursued in future.
Currently available vaccines for swine influenza are killed products
delivered by intramuscular injection, typically with an adjuvant intended to boost
the immune response (Van Reeth & Ma, 2013). Immunization by this method
stimulates the production of IgG antibodies that circulate in the blood, and
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neutralize the influenza virus to which they may come in contact.

By

neutralizing virus circulating in the blood, such antibodies protect various internal
organs from becoming infected, thus reducing or perhaps eliminating clinically
observable disease. However, protective antibodies are a strain-specific so any
mutations in the receptor binding pocket or antigenic sites or the surrounding
region will make a strain-specific vaccine not effective to neutralize these viral
variants (Hause et al., 2010; Hause et al., 2012; Ma et al., 2014; Qiao et al.,
2014). While available for humans, live attenuated swine influenza vaccines have
not been commercially available until 2017 (Vincent et al., 2012). This vaccine
candidate with a NS1 truncation appears to confer protection against some
strains or subtype of swine influenza under experimental conditions. From a
wealth of studies performed in humans, the live attenuated vaccine approach
seems to provide broader protection within different subtypes of influenza
viruses, and may provide heterosubtypic immunity. However, due to the fact that
the vaccine strains still retain the ability to replicate, reassortment among vaccine
strains and field strains may occur, potentially resulting in novel viruses that
could initiate a global influenza pandemic. Therefore use of an attenuated SIV
vaccine would carry a potential risk.

In addition to these concerns, live

attenuated vaccines used for humans and swine are still not effective in
stimulating broadly reactive antibodies, which enable to protect swine from
infections by multiple subtypes or strains.
N439G mutation attenuated the virus replication probably by disrupting the
formation of triple CD helix.

Intranasal immunization of N439G mutant
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substantially reduced nasal shedding of both subtypes (H1N1 and H3N2) in
pigs especially at day 5 post challenge. Intriguingly, intranasal immunization of
H1N1 WSN/33 strain in pigs also resulted in a similar level of protection. These
two strains are identical except for the HA segment.

N439G contains a HA

segment with N439 mutation from a currently circulating swine H1N2 virus, while
WSN/33 has its native HA segment. The other seven segments are all derived
from WSN/33 virus. Despite further work needed toward dissecting a protective
mechanism, our current hypothesis is that T cell immunity residing in viral
structural proteins such as M or NP or antibodies raised against NA protein may
play a significant role in stimulating the observed cross-subtype protection, which
will be tested in further studies. Among a panel of 18 HA2 mutants generated in
this study, 11 mutants are completely lost in infectivity. These mutants may still
have the potential in serving a good vaccine target for further development. One
approach is to express these proteins in baculovirus-based insect cells and then
test their broad-spectrum efficacy in pigs.
Developing a swine influenza vaccine that improves the breadth and
durability of protection is a high priority. Research work presented here in
exploring viral fusion as a target for swine universal vaccine development is
toward this ultimate goal. In addition to HA, investigation of the role of anti-NA
protein antibodies in protection of swine against swine influenza A virus infection
is needed. Our present study observed that some pigs possessed no detectable
HI antibody titers but were protected from infection by vaccination.

This

intriguing finding suggests that protective antibodies are not traditional
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neutralizing antibodies and they may provide protection through other
mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) (He et al.,
2016). In addition to antibody targets, the role of T cell-mediated protective
immunity in swine influenza infection and diseases should be extensively
investigated (Townsend et al., 2006). Our work described here also pinpoints
that CD4+ and CD8+ T cells may confer to the observed cross-subtype
protection.

Influenza virus is a moving target; a universal swine influenza

vaccine needs to incorporate multiple viral components that stimulate both B and
T cell immune responses, which may provide durable and broad protection for
swine against multiple influenza strains (Erbelding et al., 2018).

4.5

Acknowledgments

We thank BEI Resources, NIAID, NIH for providing the Peptide Array, NR-15433.
This work was partially supported by SDSU AES 3AH-477, by National Science
Foundation/EPSCoR

(http://www.nsf.gov/od/iia/programs/epscor/index.jsp)

award IIA-1335423, and by the state of South Dakota Governor’s Office of
Economic Development as a South Dakota Research Innovation Center. Radhey
S. Kaushik was funded and supported by USDA NIFA SDSU Agricultural
Experiment Station Hatch grant # SD00H547-15.

93

94
REFERENCES
Air, G. M. (2015). Influenza virus antigenicity and broadly neutralizing epitopes. Curr
Opin Virol 11, 113-121.
Ball, J. M., Rushlow, K. E., Issel, C. J. & Montelaro, R. C. (1992). Detailed mapping of the
antigenicity of the surface unit glycoprotein of equine infectious anemia virus by
using synthetic peptide strategies. J Virol 66, 732-742.
Belser, J. A. & Tumpey, T. M. (2018). The 1918 flu, 100 years later. Science 359, 255.
Bommakanti, G., Citron, M. P., Hepler, R. W., Callahan, C., Heidecker, G. J., Najar, T. A.,
Lu, X., Joyce, J. G., Shiver, J. W., Casimiro, D. R., ter Meulen, J., Liang, X. &
Varadarajan, R. (2010). Design of an HA2-based Escherichia coli expressed
influenza immunogen that protects mice from pathogenic challenge. Proc Natl
Acad Sci U S A 107, 13701-13706.
Bottcher-Friebertshauser, E., Garten, W., Matrosovich, M. & Klenk, H. D. (2014). The
hemagglutinin: a determinant of pathogenicity. Curr Top Microbiol Immunol 385,
3-34.
Bright, R. A., Carter, D. M., Crevar, C. J., Toapanta, F. R., Steckbeck, J. D., Cole, K. S.,
Kumar, N. M., Pushko, P., Smith, G., Tumpey, T. M. & Ross, T. M. (2008). Crossclade protective immune responses to influenza viruses with H5N1 HA and NA
elicited by an influenza virus-like particle. PLoS One 3, e1501.
Bright, R. A., Carter, D. M., Daniluk, S., Toapanta, F. R., Ahmad, A., Gavrilov, V.,
Massare, M., Pushko, P., Mytle, N., Rowe, T., Smith, G. & Ross, T. M. (2007).
Influenza virus-like particles elicit broader immune responses than whole virion
inactivated influenza virus or recombinant hemagglutinin. Vaccine 25, 38713878.
Brockwell-Staats, C., Webster, R. G. & Webby, R. J. (2009). Diversity of influenza viruses
in swine and the emergence of a novel human pandemic influenza A (H1N1).
Influenza Other Respir Viruses 3, 207-213.
Bullough, P. A., Hughson, F. M., Skehel, J. J. & Wiley, D. C. (1994a). Structure of
influenza haemagglutinin at the pH of membrane fusion. Nature 371, 37-43.
Bullough, P. A., Hughson, F. M., Treharne, A. C., Ruigrok, R. W., Skehel, J. J. & Wiley, D.
C. (1994b). Crystals of a fragment of influenza haemagglutinin in the low pH
induced conformation. J Mol Biol 236, 1262-1265.

95
Chiara, C., Silvia, F., Aurora De, M., Laura, B., Ilaria, B., Carlo, R., Arrigo, N. &
Emanuela, F. (2016). Detection of Influenza D Virus among Swine and Cattle,
Italy. Emerging Infectious Disease journal 22, 352.
Cline, T. D., Karlsson, E. A., Seufzer, B. J. & Schultz-Cherry, S. (2013). The hemagglutinin
protein of highly pathogenic H5N1 influenza viruses overcomes an early block in
the replication cycle to promote productive replication in macrophages. J Virol
87, 1411-1419.
Collin, E. A., Sheng, Z., Lang, Y., Ma, W., Hause, B. M. & Li, F. (2015). Cocirculation of
two distinct genetic and antigenic lineages of proposed influenza D virus in
cattle. Journal of virology 89, 1036-1042.
Cox, N. J. & Subbarao, K. (2000). Global epidemiology of influenza: past and present.
Annu Rev Med 51, 407-421.
Das, S. R., Puigbo, P., Hensley, S. E., Hurt, D. E., Bennink, J. R. & Yewdell, J. W. (2010).
Glycosylation focuses sequence variation in the influenza A virus H1
hemagglutinin globular domain. PLoS Pathog 6, e1001211.
Deng, L., Cho, K. J., Fiers, W. & Saelens, X. (2015). M2e-Based Universal Influenza A
Vaccines. Vaccines (Basel) 3, 105-136.
Ducatez, M. F., Pelletier, C. & Meyer, G. (2015). Influenza D Virus in Cattle, France,
2011–2014. Emerging Infectious Diseases 21, 368-371.
Easterday, B. C. (1980). The epidemiology and ecology of swine influenza as a zoonotic
disease. Comp Immunol Microbiol Infect Dis 3, 105-109.
Ekiert, D. C., Bhabha, G., Elsliger, M. A., Friesen, R. H., Jongeneelen, M., Throsby, M.,
Goudsmit, J. & Wilson, I. A. (2009). Antibody recognition of a highly conserved
influenza virus epitope. Science 324, 246-251.
Erbelding, E. J., Post, D., Stemmy, E., Roberts, P. C., Augustine, A. D., Ferguson, S.,
Paules, C. I., Graham, B. S. & Fauci, A. S. (2018). A Universal Influenza Vaccine:
The Strategic Plan for the National Institute of Allergy and Infectious Diseases. J
Infect Dis.
FDA

(2018).
Vaccines
Licensed
for
Use
in
the
United
States.
https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/
ucm093833.htm.

96
Fontana, J., Cardone, G., Heymann, J. B., Winkler, D. C. & Steven, A. C. (2012).
Structural changes in Influenza virus at low pH characterized by cryo-electron
tomography. Journal of virology 86, 2919-2929.
Forsstrom, B., Axnas, B. B., Rockberg, J., Danielsson, H., Bohlin, A. & Uhlen, M. (2015).
Dissecting antibodies with regards to linear and conformational epitopes. PLoS
One 10, e0121673.
Gack, M. U. (2014). Mechanisms of RIG-I-like receptor activation and manipulation by
viral pathogens. Journal of virology 88, 5213-5216.
Hamada, H., Garcia-Hernandez Mde, L., Reome, J. B., Misra, S. K., Strutt, T. M.,
McKinstry, K. K., Cooper, A. M., Swain, S. L. & Dutton, R. W. (2009). Tc17, a
unique subset of CD8 T cells that can protect against lethal influenza challenge. J
Immunol 182, 3469-3481.
Hause, B. M., Collin, E. A., Liu, R., Huang, B., Sheng, Z., Lu, W., Wang, D., Nelson, E. A.
& Li, F. (2014). Characterization of a novel influenza virus in cattle and Swine:
proposal for a new genus in the Orthomyxoviridae family. mBio 5, e0003100014.
Hause, B. M., Ducatez, M., Collin, E. A., Ran, Z., Liu, R., Sheng, Z., Armien, A., Kaplan,
B., Chakravarty, S., Hoppe, A. D., Webby, R. J., Simonson, R. R. & Li, F. (2013).
Isolation of a novel swine influenza virus from Oklahoma in 2011 which is
distantly related to human influenza C viruses. PLoS pathog 9, e1003176.
Hause, B. M., Oleson, T. A., Bey, R. F., Stine, D. L. & Simonson, R. R. (2010). Antigenic
categorization of contemporary H3N2 Swine influenza virus isolates using a highthroughput serum neutralization assay. J Vet Diagn Invest 22, 352-359.
Hause, B. M., Stine, D. L., Sheng, Z., Wang, Z., Chakravarty, S., Simonson, R. R. & Li, F.
(2012). Migration of the swine influenza virus delta-cluster hemagglutinin Nlinked glycosylation site from N142 to N144 results in loss of antibody crossreactivity. Clin Vaccine Immunol 19, 1457-1464.
He, W., Tan, G. S., Mullarkey, C. E., Lee, A. J., Lam, M. M., Krammer, F., Henry, C.,
Wilson, P. C., Ashkar, A. A., Palese, P. & Miller, M. S. (2016). Epitope specificity
plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity
against influenza A virus. Proc Natl Acad Sci U S A 113, 11931-11936.
Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G. & Webster, R. G. (2000). A DNA
transfection system for generation of influenza A virus from eight plasmids. Proc
Natl Acad Sci U S A 97, 6108-6113.

97
Huber, M. & Lohoff, M. (2015). Change of paradigm: CD8+ T cells as important helper
for CD4+ T cells during asthma and autoimmune encephalomyelitis. Allergo J Int
24, 8-15.
ICTV

(2018). Taxonomy. In https://talkictvonlineorg/taxonomy/
Committee on Taxonomy of Viruses.

International

Jameson, J., Cruz, J. & Ennis, F. A. (1998). Human cytotoxic T-lymphocyte repertoire to
influenza A viruses. Journal of virology 72, 8682-8689.
Johnson, K. E. E., Song, T., Greenbaum, B. & Ghedin, E. (2017). Getting the flu: 5 key
facts about influenza virus evolution. PLoS Pathogens 13, e1006450.
Joseph, U., Su, Y. C., Vijaykrishna, D. & Smith, G. J. (2017). The ecology and adaptive
evolution of influenza A interspecies transmission. Influenza Other Respir Viruses
11, 74-84.
Kashyap, A. K., Steel, J., Oner, A. F., Dillon, M. A., Swale, R. E., Wall, K. M., Perry, K. J.,
Faynboym, A., Ilhan, M., Horowitz, M., Horowitz, L., Palese, P., Bhatt, R. R. &
Lerner, R. A. (2008). Combinatorial antibody libraries from survivors of the
Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc
Natl Acad Sci U S A 105, 5986-5991.
Kashyap, A. K., Steel, J., Rubrum, A., Estelles, A., Briante, R., Ilyushina, N. A., Xu, L.,
Swale, R. E., Faynboym, A. M., Foreman, P. K., Horowitz, M., Horowitz, L.,
Webby, R., Palese, P., Lerner, R. A. & Bhatt, R. R. (2010). Protection from the
2009 H1N1 pandemic influenza by an antibody from combinatorial survivorbased libraries. PLoS Pathog 6, e1000990.
Kim, Y. J., Lee, Y. T., Kim, M. C., Lee, Y. N., Kim, K. H., Ko, E. J., Song, J. M. & Kang, S. M.
(2017). Cross-Protective Efficacy of Influenza Virus M2e Containing Virus-Like
Particles Is Superior to Hemagglutinin Vaccines and Variable Depending on the
Genetic Backgrounds of Mice. Front Immunol 8, 1730.
Lanzrein, M., Schlegel, A. & Kempf, C. (1994). Entry and uncoating of enveloped viruses.
Biochem J 302 ( Pt 2), 313-320.
Lee, N., Wong, C. K., Hui, D. S., Lee, S. K., Wong, R. Y., Ngai, K. L., Chan, M. C., Chu, Y.
J., Ho, A. W., Lui, G. C., Wong, B. C., Wong, S. H., Yip, S. P. & Chan, P. K. (2013).
Role of human Toll-like receptors in naturally occurring influenza A infections.
Influenza Other Respir Viruses 7, 666-675.

98
Lefkowitz, E. J., Dempsey, D. M., Hendrickson, R. C., Orton, R. J., Siddell, S. G. &
Smith, D. B. (2018). Virus taxonomy: the database of the International
Committee on Taxonomy of Viruses (ICTV). Nucleic Acids Res 46, D708-D717.
Leone, P., Shin, E. C., Perosa, F., Vacca, A., Dammacco, F. & Racanelli, V. (2013). MHC
class I antigen processing and presenting machinery: organization, function, and
defects in tumor cells. J Natl Cancer Inst 105, 1172-1187.
Lorusso, A., Vincent, A. L., Harland, M. L., Alt, D., Bayles, D. O., Swenson, S. L., Gramer,
M. R., Russell, C. A., Smith, D. J., Lager, K. M. & Lewis, N. S. (2011). Genetic and
antigenic characterization of H1 influenza viruses from United States swine from
2008. J Gen Virol 92, 919-930.
Luo, J., Ferguson, L., Smith, D. R., Woolums, A. R., Epperson, W. B. & Wan, X. F. (2017).
Serological evidence for high prevalence of Influenza D Viruses in Cattle,
Nebraska, United States, 2003-2004. Virology 501, 88-91.
Ma, W., Lager, K. M., Lekcharoensuk, P., Ulery, E. S., Janke, B. H., Solorzano, A.,
Webby, R. J., Garcia-Sastre, A. & Richt, J. A. (2010). Viral reassortment and
transmission after co-infection of pigs with classical H1N1 and triple-reassortant
H3N2 swine influenza viruses. J Gen Virol 91, 2314-2321.
Ma, W., Liu, Q., Qiao, C., del Real, G., Garcia-Sastre, A., Webby, R. J. & Richt, J. A.
(2014). North American triple reassortant and Eurasian H1N1 swine influenza
viruses do not readily reassort to generate a 2009 pandemic H1N1-like virus.
mBio 5, e00919-00913.
Maines, T. R., Jayaraman, A., Belser, J. A., Wadford, D. A., Pappas, C., Zeng, H., Gustin,
K. M., Pearce, M. B., Viswanathan, K., Shriver, Z. H., Raman, R., Cox, N. J.,
Sasisekharan, R., Katz, J. M. & Tumpey, T. M. (2009). Transmission and
pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice.
Science 325, 484-487.
Marcelin, G., Sandbulte, M. R. & Webby, R. J. (2012). Contribution of antibody
production against neuraminidase to the protection afforded by influenza
vaccines. Rev Med Virol 22, 267-279.
Matsuzaki, Y., Katsushima, N., Nagai, Y., Shoji, M., Itagaki, T., Sakamoto, M., Kitaoka,
S., Mizuta, K. & Nishimura, H. (2006). Clinical features of influenza C virus
infection in children. J Infect Dis 193, 1229-1235.
Matsuzaki, Y., Sugawara, K., Furuse, Y., Shimotai, Y., Hongo, S., Oshitani, H., Mizuta, K.
& Nishimura, H. (2016). Genetic Lineage and Reassortment of Influenza C
Viruses Circulating between 1947 and 2014. Journal of virology 90, 8251-8265.

99
Miotto, O., Heiny, A. T., Albrecht, R., Garcia-Sastre, A., Tan, T. W., August, J. T. &
Brusic, V. (2010). Complete-proteome mapping of human influenza A adaptive
mutations: implications for human transmissibility of zoonotic strains. PLoS One
5, e9025.
Monto, A. S. (2008). Epidemiology of influenza. Vaccine 26 Suppl 4, D45-48.
Nayak, D. P., Hui, E. K. & Barman, S. (2004). Assembly and budding of influenza virus.
Virus Res 106, 147-165.
Nedland, H., Wollman, J., Sreenivasan, C., Quast, M., Singrey, A., Fawcett, L.,
Christopher-Hennings, J., Nelson, E., Kaushik, R. S., Wang, D. & Li, F. (2018).
Serological evidence for the co-circulation of two lineages of influenza D viruses
in equine populations of the Midwest United States. Zoonoses Public Health 65,
e148-e154.
Nelson, M. I. & Vincent, A. L. (2015). Reverse zoonosis of influenza to swine: new
perspectives on the human-animal interface. Trends Microbiol 23, 142-153.
Neurath, A. R., Strick, N. & Lee, E. S. (1990). B cell epitope mapping of human
immunodeficiency virus envelope glycoproteins with long (19- to 36-residue)
synthetic peptides. J Gen Virol 71 ( Pt 1), 85-95.
Nogales, A. & Martinez-Sobrido, L. (2016). Reverse Genetics Approaches for the
Development of Influenza Vaccines. Int J Mol Sci 18.
O'Shea, J. P., Chou, M. F., Quader, S. A., Ryan, J. K., Church, G. M. & Schwartz, D.
(2013). pLogo: a probabilistic approach to visualizing sequence motifs. Nat
Methods 10, 1211-1212.
Olson, D. M. & Dinerstein, E. (2002). The Global 200: Priority Ecoregions for Global
Conservation. Annals of the Missouri Botanical Garden 89, 199-224.
Palese, P. & Shaw, M. (2007). Orthomyxoviridae: The viruses and their replication. In
Fields Virology, 5th edn, pp. 1647-1689. Edited by B. N. Fields, D. M. Knipe & P.
M. Howley. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins.
Palese, P. & Wang, T. T. (2011). Why do influenza virus subtypes die out? A hypothesis.
mBio 2.
Paul Glezen, W., Schmier, J. K., Kuehn, C. M., Ryan, K. J. & Oxford, J. (2013). The
burden of influenza B: a structured literature review. American journal of public
health 103, e43-51.

100
Perrone, L. A., Ahmad, A., Veguilla, V., Lu, X., Smith, G., Katz, J. M., Pushko, P. &
Tumpey, T. M. (2009). Intranasal vaccination with 1918 influenza virus-like
particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus
challenge. J Virol 83, 5726-5734.
Prabakaran, M., Ho, H. T., Prabhu, N., Velumani, S., Szyporta, M., He, F., Chan, K. P.,
Chen, L. M., Matsuoka, Y., Donis, R. O. & Kwang, J. (2009). Development of
epitope-blocking ELISA for universal detection of antibodies to human H5N1
influenza viruses. PLoS One 4, e4566.
Qiao, C., Liu, L., Yang, H., Chen, Y., Xu, H. & Chen, H. (2014). Novel triple reassortant
H1N2 influenza viruses bearing six internal genes of the pandemic 2009/H1N1
influenza virus were detected in pigs in China. J Clin Virol 61, 529-534.
Quast, M., Sreenivasan, C., Sexton, G., Nedland, H., Singrey, A., Fawcett, L., Miller, G.,
Lauer, D., Voss, S., Pollock, S., Cunha, C. W., Christopher-Hennings, J., Nelson,
E. & Li, F. (2015). Serological evidence for the presence of influenza D virus in
small ruminants. Vet Microbiol 180, 281-285.
Rahn, J., Hoffmann, D., Harder, T. C. & Beer, M. (2015). Vaccines against influenza A
viruses in poultry and swine: Status and future developments. Vaccine 33, 24142424.
Rajao, D. S., Anderson, T. K., Kitikoon, P., Stratton, J., Lewis, N. S. & Vincent, A. L.
(2018). Antigenic and genetic evolution of contemporary swine H1 influenza
viruses in the United States. Virology 518, 45-54.
Ran, Z., Shen, H., Lang, Y., Kolb, E. A., Turan, N., Zhu, L., Ma, J., Bawa, B., Liu, Q., Liu,
H., Quast, M., Sexton, G., Krammer, F., Hause, B. M., Christopher-Hennings, J.,
Nelson, E. A., Richt, J., Li, F. & Ma, W. (2015). Domestic pigs are susceptible to
infection with influenza B viruses. J Virol 89, 4818-4826.
Rappazzo, C. G., Watkins, H. C., Guarino, C. M., Chau, A., Lopez, J. L., DeLisa, M. P.,
Leifer, C. A., Whittaker, G. R. & Putnam, D. (2016). Recombinant M2e outer
membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c
mice. Vaccine 34, 1252-1258.
Rossman, J. S. & Lamb, R. A. (2011). Influenza virus assembly and budding. Virology
411, 229-236.
Salem, E., Cook, E. A. J., Lbacha, H. A., Oliva, J., Awoume, F., Aplogan, G. L., Hymann, E.
C., Muloi, D., Deem, S. L., Alali, S., Zouagui, Z., Fevre, E. M., Meyer, G. &
Ducatez, M. F. (2017). Serologic Evidence for Influenza C and D Virus among
Ruminants and Camelids, Africa, 1991-2015. Emerg Infect Dis 23, 1556-1559.

101
Samji, T. (2009). Influenza A: understanding the viral life cycle. Yale J Biol Med 82,
153-159.
Schotsaert, M., De Filette, M., Fiers, W. & Saelens, X. (2009). Universal M2
ectodomain-based influenza A vaccines: preclinical and clinical developments.
Expert Rev Vaccines 8, 499-508.
Seitz, C., Frensing, T., Hoper, D., Kochs, G. & Reichl, U. (2010). High yields of influenza A
virus in Madin-Darby canine kidney cells are promoted by an insufficient
interferon-induced antiviral state. J Gen Virol 91, 1754-1763.
Shao, W., Li, X., Goraya, M. U., Wang, S. & Chen, J. L. (2017). Evolution of Influenza A
Virus by Mutation and Re-Assortment. Int J Mol Sci 18.
Shin, M., Maiko, E., Tomoya, K., Akiko, T.-U., James, K. C., Kazuyuki, U., Masugi, N.,
Benjamin, H. & Taisuke, H. (2016). Influenza D Virus Infection in Herd of Cattle,
Japan. Emerging Infectious Disease journal 22, 1517.
Short, K. R., Richard, M., Verhagen, J. H., van Riel, D., Schrauwen, E. J. A., van den
Brand, J. M. A., Mänz, B., Bodewes, R. & Herfst, S. (2015). One health, multiple
challenges: The inter-species transmission of influenza A virus. One Health 1, 113.
Song, H., Qi, J., Khedri, Z., Diaz, S., Yu, H., Chen, X., Varki, A., Shi, Y. & Gao, G. F. (2016).
An Open Receptor-Binding Cavity of Hemagglutinin-Esterase-Fusion Glycoprotein
from Newly-Identified Influenza D Virus: Basis for Its Broad Cell Tropism. PLoS
pathog 12, e1005411.
Stauffer, S., Feng, Y., Nebioglu, F., Heilig, R., Picotti, P. & Helenius, A. (2014). Stepwise
priming by acidic pH and a high K+ concentration is required for efficient
uncoating of influenza A virus cores after penetration. Journal of virology 88,
13029-13046.
Sui, J., Hwang, W. C., Perez, S., Wei, G., Aird, D., Chen, L. M., Santelli, E., Stec, B.,
Cadwell, G., Ali, M., Wan, H., Murakami, A., Yammanuru, A., Han, T., Cox, N. J.,
Bankston, L. A., Donis, R. O., Liddington, R. C. & Marasco, W. A. (2009).
Structural and functional bases for broad-spectrum neutralization of avian and
human influenza A viruses. Nat Struct Mol Biol 16, 265-273.
Tong, S., Zhu, X., Li, Y., Shi, M., Zhang, J., Bourgeois, M., Yang, H., Chen, X., Recuenco,
S., Gomez, J., Chen, L. M., Johnson, A., Tao, Y., Dreyfus, C., Yu, W., McBride, R.,
Carney, P. J., Gilbert, A. T., Chang, J., Guo, Z., Davis, C. T., Paulson, J. C.,
Stevens, J., Rupprecht, C. E., Holmes, E. C., Wilson, I. A. & Donis, R. O. (2013).
New world bats harbor diverse influenza A viruses. PLoS pathog 9, e1003657.

102
Topham, D. J. & Doherty, P. C. (1998). Clearance of an influenza A virus by CD4+ T
cells is inefficient in the absence of B cells. Journal of virology 72, 882-885.
Townsend, A. R., Rothbard, J., Gotch, F. M., Bahadur, G., Wraith, D. & McMichael, A. J.
(2006). The epitopes of influenza nucleoprotein recognized by cytotoxic T
lymphocytes can be defined with short synthetic peptides. 1986. J Immunol 176,
5141-5150.
van de Sandt, C. E., Kreijtz, J. H. & Rimmelzwaan, G. F. (2012). Evasion of influenza A
viruses from innate and adaptive immune responses. Viruses 4, 1438-1476.
Van Reeth, K. & Ma, W. (2013). Swine influenza virus vaccines: to change or not to
change-that's the question. Curr Top Microbiol Immunol 370, 173-200.
Vanderven, H. A., Jegaskanda, S., Wheatley, A. K. & Kent, S. J. (2017). Antibodydependent cellular cytotoxicity and influenza virus. Curr Opin Virol 22, 89-96.
Vijaykrishna, D., Holmes, E. C., Joseph, U., Fourment, M., Su, Y. C., Halpin, R., Lee, R.
T., Deng, Y. M., Gunalan, V., Lin, X., Stockwell, T. B., Fedorova, N. B., Zhou, B.,
Spirason, N., Kuhnert, D., Boskova, V., Stadler, T., Costa, A. M., Dwyer, D. E.,
Huang, Q. S., Jennings, L. C., Rawlinson, W., Sullivan, S. G., Hurt, A. C., MaurerStroh, S., Wentworth, D. E., Smith, G. J. & Barr, I. G. (2015). The contrasting
phylodynamics of human influenza B viruses. eLife 4, e05055.
Vincent, A. L., Ma, W., Lager, K. M., Janke, B. H. & Richt, J. A. (2008). Swine influenza
viruses a North American perspective. Adv Virus Res 72, 127-154.
Vincent, A. L., Ma, W., Lager, K. M., Richt, J. A., Janke, B. H., Sandbulte, M. R., Gauger,
P. C., Loving, C. L., Webby, R. J. & Garcia-Sastre, A. (2012). Live attenuated
influenza vaccine provides superior protection from heterologous infection in
pigs with maternal antibodies without inducing vaccine-associated enhanced
respiratory disease. J Virol 86, 10597-10605.
Vincent, A. L., Perez, D. R., Rajao, D., Anderson, T. K., Abente, E. J., Walia, R. R. &
Lewis, N. S. (2017). Influenza A virus vaccines for swine. Vet Microbiol 206, 3544.
Wang, D., Harmon, A., Jin, J., Francis, D. H., Christopher-Hennings, J., Nelson, E.,
Montelaro, R. C. & Li, F. (2010a). The lack of an inherent membrane targeting
signal is responsible for the failure of the matrix (M1) protein of influenza A virus
to bud into virus-like particles. Journal of virology 84, 4673-4681.
Wang, M. & Veit, M. (2016). Hemagglutinin-esterase-fusion (HEF) protein of influenza C
virus. Protein Cell 7, 28-45.

103
Wang, T. T., Tan, G. S., Hai, R., Pica, N., Ngai, L., Ekiert, D. C., Wilson, I. A., GarciaSastre, A., Moran, T. M. & Palese, P. (2010b). Vaccination with a synthetic
peptide from the influenza virus hemagglutinin provides protection against
distinct viral subtypes. Proc Natl Acad Sci U S A 107, 18979-18984.
Wang, T. T., Tan, G. S., Hai, R., Pica, N., Petersen, E., Moran, T. M. & Palese, P. (2010c).
Broadly protective monoclonal antibodies against H3 influenza viruses following
sequential immunization with different hemagglutinins. PLoS pathog 6,
e1000796.
Wanzeck, K., Boyd, K. L. & McCullers, J. A. (2011). Glycan shielding of the influenza virus
hemagglutinin contributes to immunopathology in mice. Am J Respir Crit Care
Med 183, 767-773.
WHO

(2018).
Influenza
(Seasonal).
http://wwwwhoint/mediacentre/factsheets/fs211/en/:
World
Organization.

In
Health

Wiley, D. C. & Skehel, J. J. (1987). The structure and function of the hemagglutinin
membrane glycoprotein of influenza virus. Annu Rev Biochem 56, 365-394.
Wong, K. K., Gambhir, M., Finelli, L., Swerdlow, D. L., Ostroff, S. & Reed, C. (2013).
Transmissibility of variant influenza from Swine to humans: a modeling
approach. Clin Infect Dis 57 Suppl 1, S16-22.
Wu, X., Wu, X., Sun, Q., Zhang, C., Yang, S., Li, L. & Jia, Z. (2017). Progress of small
molecular inhibitors in the development of anti-influenza virus agents.
Theranostics 7, 826-845.
Yu, X., Tsibane, T., McGraw, P. A., House, F. S., Keefer, C. J., Hicar, M. D., Tumpey, T.
M., Pappas, C., Perrone, L. A., Martinez, O., Stevens, J., Wilson, I. A., Aguilar, P.
V., Altschuler, E. L., Basler, C. F. & Crowe, J. E., Jr. (2008). Neutralizing
antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature
455, 532-536.
Zhai, S.-L., Zhang, H., Chen, S.-N., Zhou, X., Lin, T., Liu, R., Lv, D.-H., Wen, X.-H., Wei,
W.-K., Wang, D. & Li, F. (2017). Influenza D Virus in Animal Species in
Guangdong Province, Southern China. Emerging Infectious Disease journal 23.
Zhao, R., Cui, S., Guo, L., Wu, C., Gonzalez, R., Paranhos-Baccala, G., Vernet, G., Wang,
J. & Hung, T. (2011). Identification of a highly conserved H1 subtype-specific
epitope with diagnostic potential in the hemagglutinin protein of influenza A
virus. PLoS One 6, e23374.

104
Zhou, Z., Gao, X., Wang, Y., Zhou, H., Wu, C., Paranhos-Baccala, G., Vernet, G.,
Guo, L. & Wang, J. (2014). Conserved B-cell epitopes among human bocavirus
species indicate potential diagnostic targets. PLoS One 9, e86960.

